WO2013123379A2 - Nanopore sensor for enzyme-mediated protein translocation - Google Patents
Nanopore sensor for enzyme-mediated protein translocation Download PDFInfo
- Publication number
- WO2013123379A2 WO2013123379A2 PCT/US2013/026414 US2013026414W WO2013123379A2 WO 2013123379 A2 WO2013123379 A2 WO 2013123379A2 US 2013026414 W US2013026414 W US 2013026414W WO 2013123379 A2 WO2013123379 A2 WO 2013123379A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- nanopore
- clpx
- pore
- translocated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
- C12M47/06—Hydrolysis; Cell lysis; Extraction of intracellular or cell wall material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/48707—Physical analysis of biological material of liquid biological material by electrical means
- G01N33/48721—Investigating individual macromolecules, e.g. by translocation through nanopores
Definitions
- the present invention relates to the field of single molecule protein analysis and also to the field of nanopore analysis.
- Nanopores have been used for various biosensing applications, the most popular of which has been DNA analysis (e.g. sequencing). Similarly, nanopore sequencing of proteins has also been envisioned.
- proteins are generally not uniformly charged (making it difficult to drive translocation via an applied voltage) and they also fold into complex, large, and stable structures that cannot transverse a nanopore' s aperture. More specifically, the reasons that protein sequencing is technically more challenging than DNA sequencing include: i) twenty different natural amino acids are found in proteins compared to four nucleotides for DNA sequencing (not including post- translational and epigenetic modifications); ii) both tertiary and secondary structures must be unfolded to allow the denatured protein to thread through the nanopore sensor in single file order; and iii) processive unidirectional translocation of the denatured polypeptide through the nanopore electric field must be achieved despite non-uniform charge along the polypeptide backbone.
- the present invention provides a device for translocating a protein through a nanopore, comprising: a membrane having nanopore therein, said membrane separating a chamber into a cis side and a tram side, wherein the protein is to be added to the cis side and translocated through the nanopore to the trans side; and a protein translocase enzyme, on one side of said chamber, which binds to and translocates the protein through the nanopore. Translocation will occur in a sequential order, that is, in a defined sequence of amino acid residues passing into the nanopore, which will generally follow the primary amino acid sequence of the protein. Multiple proteins can be translocated one at a time.
- the present invention also provides a device for translocating a protein through a nanopore, comprising: a nanopore in a membrane, said membrane separating a fluidic chamber into a cis side and a trans side, wherein a protein to be translocated is added to the cis side and is translocated through the nanopore to the trans side; a circuit for providing a voltage gradient between the cis side and the trans side and for measuring ionic current flowing through the nanopore; and a specific enzyme, such as a protein translocase and/or an NTP driven unfoldase added to the fluid chamber, e.g. by being allowed to become attached to said nanopore on the cis side, or by addition in solution to the trans side.
- a specific enzyme such as a protein translocase and/or an NTP driven unfoldase added to the fluid chamber, e.g. by being allowed to become attached to said nanopore on the cis side, or by addition in solution to the trans side.
- the nanopore is defined by a pore protein.
- the pore protein is a-hemolysin.
- the protein translocase is an NTP driven unfoldase which operates on the protein molecule to be translocated.
- the NTP driven unfoldase is an AAA+ enzyme.
- the AAA+ enzyme is a combination of subunits of E. coli ClpX.
- the circuit for detection of protein translocation comprises a patch clamp amplifier applying a positive voltage to the trans side.
- the patch clamp amplifier maintains a constant voltage and measures changes in current.
- the device comprises a computer, attached to the patch clamp amplifier, for rapidly recording changes in ionic current through the nanopore.
- an ionic current signature is obtained which can detect on the order of 1 to 100,000 fluctuations per second, providing information about individual amino acids translocating through the pore. For example, recording at 100kHz can be used to produce one data point every 10 The data can be correlated to structural features of the protein being translocated.
- a system for translocating a protein through a nanopore comprising a nanopore in a membrane separating a fluidic chamber into a cis side and a trans side, wherein a protein to be translocated is added to the cis side and is translocated through the nanopore to the trans side; said fluidic chamber comprising an ionic buffer containing an enzyme cofactor such as NTP (nucleoside 5'- triphosphate, e.g.
- NTP nucleoside 5'- triphosphate
- ATP and/or GTP ATP and/or GTP
- a non-denatured protein to be translocated on the cis side
- a circuit for providing a voltage between the cis side and the trans side and measuring ionic current flowing through the nanopore and a protein translocase such as an NTP driven unfoldase in solution in the chamber on the cis side.
- the nanopore is defined by a pore protein such as a multimeric pore protein and the protein translocase such as an NTP driven unfoldase is attached to the multimeric pore protein.
- the protein translocase may be covalently or non-covalently attached to the pore protein, and may be on the cis side, the trans side or both sides of the membrane and pore protein.
- the protein to be translocated is a non-denatured protein (i.e. in its native state) and, further, comprises an exogenous sequence comprising a targeting domain for the protein to be targeted to pass through the nanopore and contact the NTP driven unfoldase.
- the NTP driven unfoldase is ClpX and the nanopore protein is a- hemolysin.
- the targeting domain in the exogeneous sequence serves to guide the protein to the nanopore.
- the targeting domain may be configured to be affected by the voltage across the nanopore.
- the targeting domain comprises at about 5 negatively charged amino acids or at least about 5- 30 negatively charged amino acids and is drawn to the positive side of the chamber by a voltage gradient applied between the cis side and the trans side.
- the present invention also provides a method for translocating a non-denatured protein through a nanopore, comprising the steps of: providing a device for translocating a protein through a nanopore, said device comprising a nanopore in a membrane separating a fluidic chamber into a cis side and a trans side, wherein a protein to be translocated is added to the cis side and is translocated through the nanopore to the trans side; a circuit for providing a voltage between the cis side and the trans side and measuring ionic current flowing through the nanopore; and a protein translocase in solution on the trans side; adding to said fluidic chamber a buffer containing NTPs (where the translocase is NTP-driven); optionally adding a non-denatured protein to the cis side; allowing the non-denatured protein to be captured or threaded through the nanopore (e.g.
- the step of measuring current changes comprises measuring current changes for states of (i) open channel in the nanopore, (ii), capture of the nondenatured protein by the nanopore, and (iii) passage of a protein from (ii) through the nanopore.
- the measuring comprises detecting differences between states (i), (ii) and (iii).
- the measuring comprises measuring differences during state (iii) caused by amino acid structure of the protein passing through the nanopore.
- the method may further comprise the step of measuring a state of binding of the NTP driven unfoldase to the nondenatured protein and translocation of the unfoldase toward the nanopore, which occurs as a state between states (ii) and (iii). This would result in measuring four states.
- the nanopore is defined by a pore protein.
- the pore protein is a- hemolysin.
- the NTP driven unfoldase is attached to the pore protein.
- the NTP driven unfoldase is an AAA+ enzyme.
- the AAA+ enzyme is ClpX.
- the circuit comprises a patch clamp amplifier applying a constant voltage between the cis chamber and the trans chamber.
- the nanopore is defined by a- hemolysin or another multimeric pore protein.
- the pore protein does not need to be functionalized; that is it may be used as the protein exits in its native environment; it does not need to have any molecular structures added to it to attach or bind the protein being translocated. That is, it may be generic for translocation of any protein sequence, and does not specifically bind to or recognize the protein to be translocated.
- the protein to be translocated is also preferably in a native form. It may, in certain embodiments of the present invention, have attached to it a molecular structure for improving "threading" of the protein through the nanopore.
- the protein to be translocated comprises an exogeneous sequence comprising a targeting domain for the protein translocase.
- the targeting domain may comprise at least about 5-30 amino acids, or 10-30 amino acids.
- the amino acids may be negatively charged amino acids, e.g. 30-100 glutamate or aspartate residues, or other negatively charged synthetic monomers, e.g. dextran sulfate, located at an amino or carboxy terminus of the protein to be translocated.
- the amino acids may also be positively charged, e.g. arginine or lysine, if the voltage polarity was reversed from that exemplified below.
- the protein to be translocated is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoe
- translocase serves to unfold the protein as it traverses the voltage gradient across the nanopore.
- Figure 1A is a diagrammatic drawing (cartoon) of a nanopore sensor with a single AHL (a-hemolysin) pore embedded in a lipid bilayer.
- Figure IB is a diagrammatic drawing that shows a protein captured in the nanopore.
- Figure 1C is a diagrammatic drawing that shows the engineered proteins used in the present examples for translocation.
- Figure 2A, 2B is a diagrammatic representation and plot that shows the ionic current traces during ClpX-mediated protein translocation.
- Figure 2C is a trace that shows the ionic current traces during protein S2-35 translocation.
- Figure 2D is a trace that shows the ionic current traces during protein S2-148 translocation.
- Figure 3A, 3B and 3C is a series of bar graphs that shows the comparison of ionic current state dwell times for the three model proteins.
- Figure 4A-D is a diagrammatic representation and current trace that shows the ionic current traces during voltage-mediated protein translocation without the presence of ClpX in the trans solution. After a highly variable capture duration ( ⁇ 5 sec - > 2 min), all substrates tested will eventually unfold and translocate due to the applied voltage. No ramping states are observed, detailed signal features are lost from S2-35 and S2-148 linker states, and all states have more widely distributed durations as compared to ClpX-mediated events.
- Figure 4A shows the ionic current traces during voltage-mediated SI translocation. Compared to Fig.
- FIG. 4B illustrates the model of voltage-mediated protein translocation.
- Figure 4B shows four cartoon structures, i. through iv. Cartoons i-iv correspond to ionic current states i-iv in Fig. 4A.
- Figure 4C shows the ionic current traces during voltage-mediated S2-35 translocation. Ramping of states iii and vi are absent and resolution of state v (Fig. 2C) is diminished.
- Figure 4D shows the ionic current traces during voltage-mediated S2-148 exhibits similar behavior to S2-35 with the corresponding states omitted (Fig. 2D).
- Figure 5 is a frequency bar graph that demonstrates the comparison of ionic current state dwell times of ClpX-dependent (with ClpX present in the trans side) ramping state iii for the three model proteins.
- Figure 8 is a frequency bar graph that shows the comparison of ionic current dwell times of the putative Smt3 domain translocation states iv and vii for the three model proteins.
- the black bars represent dwell times for events that included ramping state iii (ClpX-driven).
- Figure 9 is a frequency bar graph that shows state v dwell times for S2-35
- the black bars represent dwell times for events that included ramping state iii (ClpX-driven).
- Figure 10 is a diagrammatic representation that illustrates a fusion protein of ClpP/a- HL embedded within a lipid membrane.
- Described herein is a system for translocating an individual protein through a nanopore so as to enable information about the protein, e.g. amino acid content of the protein, to be obtained through electronic signals reflecting passage of the protein through the nanopore.
- the present device achieves the enzyme-controlled unfolding and translocation of native proteins through a nanopore sensor using the protein translocase in such a way that circuitry between the cis side and the trans side can monitor and record signals indicative of the amino acid content of the protein, e.g. amino acid sequence.
- an array of nanopores and circuits can be provided. These can be in a single chamber or in multiple chambers.
- the present device operates to translocate a substrate protein 101 and comprises a pore protein 102 (cc-hemolysin, or "AHL") embedded in a lipid bilayer 104 that is comprised in an ⁇ 25 ⁇ aperture in a membrane 106 separating a fluid compartment into a cis side, containing the protein 101, and a trans side, to which the protein 101 is going to be translocated through the pore 102.
- the device includes a controllable amplifier 108 for applying a constant voltage between a positive electrode 110 on the trans side and a negative electrode on the cis side.
- a protein translocase 109 exemplified below as ClpX, is present on the trans side of the chamber.
- Amplifier 108 also provides a circuitry for detecting and, preferably, recording changes in ionic current (i.e. flow of ions such as the depicted CI- and K+) that take place very rapidly as the protein 101 translocates.
- ionic current i.e. flow of ions such as the depicted CI- and K+
- data were collected at 100 kHz, but high speed data sampling devices are known and may be used (e.g. 200MHz Model 7150 from Pentek, Inc).
- Figure IB shows a detailed view of the AHL pore protein 102 in the lipid bilayer 104 and also shows the protein translocase 109 which is on the trans side and which is acting on protein 101 which in the cartoon is threaded through and is on both sides of the pore 102.
- a model substrate protein bearing a Smt3 domain at its amino-terminus is coupled by a charged flexible linker to an ssrA tag at its carboxy- terminus.
- the charged, flexible tag is threaded through the nanopore into the trans- side solution, while the folded Smt3 domain at this point prevents complete translocation of the captured protein.
- ClpX present in the trans solution binds the C-terminal ssrA sequence of the substrate protein. Fueled by ATP hydrolysis, ClpX translocates along the protein tail toward the channel, and subsequently catalyzes unfolding and translocation of the Smt3 domain(s) through the pore. The Smt3 domains are folded, while the linker(s) are not.
- Smt3 is further described in US 2009/0280535, "SUMO Fusion Protein Expression System for Producing Native
- Proteins “Demonstrated in the examples below is enzymatic control of protein unfolding and translocation through the cc-hemolysin nanopore. Segments of each substrate protein were discerned based on amino acid composition as they passed through the circa 50-Angstrom- long trans-membrane pore lumen (nanopore).
- the translocase enzyme used is selected and controlled to enable the device to provide protein sequence information.
- the enzyme is selected from a class of enzymes termed generally herein "protein translocases,” referring to the ability of such enzymes to cause physical movement relative to a substrate.
- the substrate protein is tagged for recognition by the translocase.
- ssrA tag Various ssrA tags are known, as this is the mechanism used in several bacterial species for marking proteins to be degraded by a ClpX protease system.
- the ssrA tag is a C-terminal 11 residue AA sequence (shown at the end of SEQ ID NO: 5) of which subsets of this sequence are recognized by ClpA or ClpX uniquely.
- a protein nanopore protein or a chimeric nanopore as shown in Figure 10 may be embedded in a thin insulting membrane (for example, a lipid bilayer or a graphene sheet) separating two conductive aqueous solutions of differential voltage. Sensing would be imparted by the flow of ionic current through the nanopore; as the protein translocated or otherwise interacted with the pore, blockades of ion flow would occur, providing an electronic signal for subsequent analysis.
- This protein nanopore or chimeric nanopore could also be utilized in arrays or lab-on-chip devices for paralleled separation and/or purification of target proteins in mass.
- the invention may be carried out in various apparatus for nanopore analysis, such as an array or a chip.
- the apparatus may be any of those described in International Application No. PCT/GB08/004127 (published as WO 2009/077734, entitled “Formation of layers of amphiphilic molecules"), PCT/GB 10/000789 (published as WO 2010/122293 entitled “Lipid bilayer sensor array” ), International Application No. PCT/GB 10/002206 (published as WO 00/28132 entitled "Biochemical analysis instrument”) or International Application No.
- any range set forth is intended to include any sub-range within the stated range, unless otherwise stated.
- a range of 120 to 250 is intended to include a range of 120-121, 120-130, 200-225, 121-250 etc.
- the term "about” has its ordinary meaning of approximately and may be determined in context by experimental variability. In case of doubt, “about” means plus or minus 5% of a stated numerical value.
- nanopore is used herein in its conventional sense to refer to any small hole or channel of the order of 0.5 to 10 nanometers in internal diameter.
- nanopore includes both biological (e.g. a-hemolysin) or artificial nanopores.
- the present nanopores can vary in dimensions, for example it can have a diameter of between about 0.5 nm and 10 nm in size.
- the diameter can be about 0.5 nm, 1 nm, 1.25 nm, 1.5 nm, 1.75 nm, 2 nm, 2.25 nm, 2.5 nm, 2.75 nm, 3 nm, 3.5 nm, 4 nm, 4.5 nm, 5 nm, 6 nm, 7 nm, 8 nm, 9nm, 10 nm, or any dimension there between.
- Biological nanopores can be created by pore proteins. Artificial nanopores can be made by micromolding or drilling. They also can be made by etching a somewhat larger hole (several tens of nanometers) in a piece of silicon, and then gradually filling it in using ion-beam sculpting methods which results in a much smaller diameter hole.
- pore protein is used herein in its conventional sense to refer to pore- forming proteins (PFPs) which assemble into ring-like structures in the vicinity of the target membrane to expose sufficient hydrophobicity to drive spontaneous bilayer insertion. Pore proteins are typically (but not exclusively) produced by bacteria, such C. septicum and S. aureus.
- PFPs can be alpha-pore-forming toxins, such as Cytolysin A of E. coli; or beta-pore- forming toxins, such as a-hemolysin and Panton- Valentine leukocidin (PVL); or binary toxins, such as Anthrax toxin; or cholesterol-dependent cytolysins (CDCs), such as
- a preferred pore protein is a-hemolysin (AHL).
- a-hemolysin is used herein in its conventional sense to refer to a pore- forming toxin from the bacterium, Staphylococcus aureus, ⁇ -hemolysin consists mostly of beta-sheets (68%) with only about 10% alpha-helices.
- the hla gene on the S. aureus chromosome encodes the 293 residue protein monomer, which forms heptameric units on the cellular membrane to form a complete beta-barrel pore. This structure allows the toxin to perform its major function, development of pores in the cellular membrane.
- membrane is used herein in its conventional sense to refer to a thin, filmlike structure.
- the membrane separating the cis and trans chambers comprises at least one pore or channel.
- Membranes can be generally classified into synthetic membranes and biological membranes. Any membrane may be used in accordance with the invention.
- Suitable membranes are well-known in the art.
- the membrane is preferably an amphiphilic layer.
- An amphiphilic layer is a layer formed from amphiphilic molecules, such as phospholipids, which have both at least one hydrophilic portion and at least one lipophilic or hydrophobic portion.
- the amphiphilic layer may be a monolayer or a bilayer.
- the amphiphilic molecules may be synthetic or naturally occurring. Non-naturally occurring amphiphiles which form a monolayer are known in the art and include, for example, block copolymers (Gonzalez-Perez et al., Langmuir, 2009, 25, 10447-10450).
- lipid bilayer is used herein in its conventional sense to refer to a thin polar membrane made of two layers of lipid molecules, arranged so that the hydrophilic phosphate heads point "out” to the water on either side of the bilayer and the hydrophobic tails point "in” the core of the bilayer.
- the lipid bilayers are usually a few nanometers in width, and they are impermeable to most charged water-soluble molecules.
- Lipid bilayers are large enough structures to have some of the mechanical properties of liquids or solids.
- the area compression modulus Ka, bending modulus Kb, and edge energy, can be used to describe them.
- Solid lipid bilayers also have a shear modulus, but like any liquid, the shear modulus is zero for fluid bilayers.
- Lipid bilayers can also be supported by solid substrates having apertures, such as heat shrink tubing, fused silica, borosilicate glass, mica, and oxidized silicon. Lipids may be applied, e.g., through Langmuir-Blodgett technique, vesicle fusion processes or the combination of the two.
- NTP is used herein in its conventional sense to refer to nucleoside triphosphate, a containing a nucleoside bound to three phosphates, making it a nucleotide.
- NTP can be adenosine triphosphate (ATP), guanosine triphosphate (GTP), cytidine triphosphate (CTP), 5-methyluridine triphosphate (m 5 UTP ), uridine triphosphate (UTP), deoxyadenosine triphosphate (dATP), deoxyguanosine triphosphate (dGTP), deoxycytidine triphosphate (dCTP), deoxythymidine triphosphate (dTTP) or deoxyuridine triphosphate (dUTP).
- ATP adenosine triphosphate
- GTP guanosine triphosphate
- CTP 5-methyluridine triphosphate
- UTP uridine triphosphate
- UTP uridine triphosphate
- dATP deoxyadenosine triphosphate
- dGTP deoxyguanosine triphosphate
- dCTP deoxythymidine triphosphate
- dUTP deoxyuridine triphosphate
- NTP also refers
- NTP driven unfoldase is used herein in its conventional sense to refer to an NTP-dependent enzyme that catalyzes protein unfolding.
- the very common NTP driven unfoldases are ATP-dependent proteases, such as proteasomal ATPases, AAA proteases, or AAA+ enzymes (defined below); membrane fusion proteins, such as NSF (N- Ethylmaleimide-sensitive fusion protein)/Sacl8p (N-Ethylmaleimide- sensitive fusion protein homologue in yeast) or p97 / VCP / Cdc48p (97-kDa valosin-containing protein); Pexlp and Pex6p (peroxisomal ATPase); Katanin and SKD1 (Vps4p homolog in mouse)/Vps4p
- TIP49a/TIP49 and TIP49b/TIP48 eukaryotic RuvB-like protein.
- AAA+ enzyme is used herein in its conventional sense to refer to the
- AAA+ superfamily of enzymes.
- AAA+ is an abbreviation for ATPases Associated with diverse cellular Activities. They share a common conserved module of approximately 230 amino acid residues. This is a large, functionally diverse protein family belonging to the AAA+ superfamily of ring-shaped P-loop NTPases, which exert their activity through the energy-dependent remodeling or translocation of macromolecules. Examples include ClpAP, ClpXP, ClpCP, HslVU and Lon in bacteria and their homologues in mitochondria and chloroplasts.
- AAA+ enzymes (sometimes referred to as unfoldases or proteases) consist of regulatory (ATPase) and proteolytic subunits, while Lon is a single polypeptide containing both regulatory and proteolytic domains.
- ClpX and ClpA dock with ClpP to form ClpXP and ClpAP proteases
- HslU docks with HslV to form another protease, HslVU.
- ClpA and ClpX form hexamers, in contrast to ClpP which forms heptamers.
- HslU and HslV each form hexamers, although HslU heptamers have also been reported.
- the regulatory subunits ClpA, ClpX and HslU function as chaperones. Further details on ClpX may be found in Maillard et al., "ClpX(P) generates mechanical force to unfold and translocate its protein substrates," Cell 145:459-4669 (April 29, 2011). As reported there, the ClpX motor shares is basic design with other AAA+ enzymes, including prokaryotic ClpA, ClpB, Hslu, FtsH or Lon.
- the AAA+ enzyme is also referred to as an
- AAA+ molecular motor Further description of the AAA+ superfamily is found in Ogura et al. "AAA+ superfamily ATPases” common structure-diverse function," Genes to Cells, 6:575-597 (2001). AS described there, the AAA+ family members associated with mitochondria are Bcslp, Lon/Pimlp, ClpX and Hsp78.
- HslU is used herein in its conventional sense to refer to ATP-dependent protease ATPase subunit HslU, also called unfoldase HslU. HslU is a member of the HsplOO and Clp family of ATPase.
- Lon protease is used herein in its conventional sense to refer to a family of proteases found in archaea, bacteria and eukaryotes. Lon proteases are ATP-dependent serine peptidases belonging to the MEROPS peptidase family S16 (lon protease family, clan SF). In the eukaryotes the majority of the Lon proteases are located in the mitochondrial matrix. In yeast, the Lon protease PIMl is located in the mitochondrial matrix. It is required for mitochondrial function, it is constitutively expressed but is increased after thermal stress, suggesting that PIMl may play a role in the heat shock response.
- protein translocase is used herein in its conventional sense to mean a protein-binding polypeptide, such as a polypeptide which is able to control movement of a protein substrate, for example an enzyme, enzyme complex, or a part of an enzyme complex that operates on a protein substrate and moves it relative to the enzyme in a processive manner, i.e. as a function of enzymatic activity.
- processing is understood in the art to refer to a stepwise activity in which the enzyme "processes” the substrate in a number of steps.
- the protein translocase generally processes the protein to be translocated in a sequential manner, that is, moving along the primary amino acid sequence.
- a number of enzymes also commonly called “unfoldases” are included in this definition, in particular NTP driven unfoldases.
- AAA+ enzyme superfamily and the ClpX member of this superfamily is also specifically included in this definition.
- protein translocase proteases such as Lon protease and HsIU, which enzymes are either modified to eliminate the enzymatic cleavage activity of the enzyme or arranged so that cleavage occurs after the sequence is translocated through the nanopore.
- proteases such as Lon protease and HsIU
- Other exemplary protein translocases are related to ClpX, (which is also an unfoldase), e.g. ClpA, mitochondrial protein translocases TOM (translocase of the outer membrane) or other TOM and TIM proteins.
- the chosen protein translocase can also be any part of the mitochondrial protein translocase complex, such as the chaperones, TOM import receptor, TOM channel complex, and "motor" proteins.
- ClpX enzyme of "ClpX” is used herein in its conventional sense to refer to a member of the HSP (heat- shock protein) 100 family having the Uniprot designation clpX and having the 424 amino acid sequence given there, processed into mature form, as a subunit. ClpX subunits associate to form a six-membered (homohexameric) ring that is stabilized by binding of ATP or nonhydroly sable analogs of ATP.
- the N-terminal domain of ClpX is a C4-type zinc binding domain (ZBD) involved in substrate recognition. ZBD forms a very stable dimer that is essential for promoting the degradation of some typical ClpXP substrates such as 10 and MuA.
- ClpA refers to the UniProt/Swiss-Prot entry clpA, which has a 758 amino acid sequence given there for the ClpA subunit. It forms a complex of six ClpA subunits assembled into a hexameric ring in the presence of ATP. It is a component of the ClpAP complex composed of six ClpA subunits assembled into a hexameric ring in the presence of ATP, and fourteen ClpP subunits arranged in two heptameric rings. Binds to ClpS.
- the term "non-denatured protein" is used herein in its conventional sense, i.e.
- denatured protein which usually is insoluble and aggregated.
- negatively charged amino acids is used herein in its conventional sense, i.e. meaning proteins that have surfaces rich with negatively charged amino acids like glutamate and aspartate.
- Translocation of proteins through a nanopore sensor device offers a number of possible applications, including sequencing, structure/fold analysis, purification/separation, intracellular protein delivery, and insight into the mechanics of enzymes driving the translocating polypeptide.
- proteins are generally not uniformly charged (making it difficult to drive translocation via an applied voltage) and fold into complex, large, and stable structures that cannot transverse a nanopore' s aperture.
- unfolding and translocation of natively folded proteins through a protein nanopore may be accomplished via a variety of enzymes, exemplified by the E. coli ClpX (or other types of protein translocases/unf oldases) .
- the present methods and devices may be used to measure one or more characteristics of the protein being translocated.
- a variety of different types of measurements may be made. This includes without limitation: electrical measurements and optical measurements. Possible electrical
- measurements include: current measurements, impedance measurements, tunnelling measurements (Ivanov AP et al., Nano Lett. 2011 Jan 12;l l(l):279-85), and FET
- the measurement may be a transmembrane current measurement such as measurement of ionic current flowing through the pore.
- the signal measurement is typically indicative of the identity of the protein or the amino acids in the protein.
- the signal can therefore be used to characterize, such as sequence, the protein as discussed above.
- E. coli ClpX was used in the working example of the present device; it was selected for initial work because it generates sufficient mechanical force (>20 pN) to denature stable protein folds, and because it translocates along proteins at a suitable rate for primary sequence analysis by nanopore sensors (up to 80 amino acids per second).
- ClpX is part of the ClpXP pro teas ome-like complex.
- ClpP is composed of a diheptameric cylinder-like protease that binds at one or both ends a regulatory hexameric ATP-dependent unfoldase/translocase complex (e.g. ClpX).
- ClpX acts as a gate that allows for tagged proteins to enter into the inner lumen of the ClpP protease complex for subsequent degradation.
- the ATP-dependent unfoldase/translocase activity of the hexameric protein complex, ClpX is employed to unfold and thread proteins through a nanopore.
- ClpX may be prepared (and was prepared here) as described in Martin et al. "Rebuilt AAA+ Motors reveal operating principles for ATP-fuelled machines," Nature 437: 1115-1120 (2005).
- a variety of alternative enzymes may serve the function of the protein translocase in the present method and device. As described there, combinations of 2, 3 or 6 ClpX-deltaN subunits, lacking N terminal amino acids 1-60, linked with a 20 amino acid long linker were prepared as a single polypeptide chain.
- AAA+ ATPases The repertoire of cellular functions involving AAA+ ATPases is diverse. A subset of AAA+ proteins is not active as ATPases and some do not even bind ATP. It seems however, that these proteins form complexes with other family members which do serve as ATPases. However, the ATPase subunits or domains of all known ATP-dependent proteases belong to the AAA+ family.
- a suitable AAA+ enzyme is Clp/HsplOO ATPases.
- Clp/HsplOO ATPases are responsible for selecting protein targets.
- the two different bacterial ATPases ClpX and ClpA impart distinct substrate preferences to the ClpP peptidase.
- the ssrA degradation sequence an 11-residue peptide that is appended to polypeptides stalled on the ribosome, is recognized by both ClpX and ClpA. Mutational analysis of the ssrA sequence revealed that this same tag is recognized by the two unfolding enzymes via different residues, further confirming the distinct binding preferences of each ATPase.
- Clp/HsplOO enzymes Using the energy from ATP-hydrolysis, Clp/HsplOO enzymes actively direct structural changes in their substrates. These ATP-driven structural changes result in two distinct biological outcomes for the protein substrates: degradation or remodeling.
- ClpA based on its ability to degrade casein, was the first prokaryotic Clp/ HsplOO protein functionally identified. Accordingly, the degradation pathway for the Clp/HsplOO proteins is the better characterized of the two processes.
- Clp/HsplOO-facilitated protein degradation first, the Clp/HsplOO component recognizes and selects a target protein.
- the enzyme binds to a short peptide sequence (e.g., the ssrA degradation tag) usually located near either the C or N terminus of the substrate. Then, in a reaction that requires multiple cycles of ATP-hydrolysis, the enzyme unfolds and directionally translocates the target substrate to the peptidase chamber where it is degraded.
- a short peptide sequence e.g., the ssrA degradation tag
- Mitochondrial protein translocases may also be used. These may be translocases TOM or TIM from human or eukaryotic cells, such as TOMM20 (translocase of outer
- TOMM22 mitochondrial membrane 20 homolog
- TOMM22 mitochondrial import receptor subunit 22 homolog
- TOMM40 mitochondrial membrane 40 homolog
- TOM7 translocase of mitochondrial outer membrane 7
- TOMM7 translocase of outer membrane
- TOMM40 is embedded into outer membranes of mitochondria and is required for the movement of proteins into mitochondria. More, precisely, TOMM40 is the channel-forming subunit of a translocase of the mitochondrial outer membrane (TOM) that is essential for protein transport into mitochondria
- Another alternative protein translocase may be prepared from the Sec family of translocases. These include SecB (chaperone protein), SecA (ATPase), SecY (internal membrane complex in prokaryotes), SecE (interal membrane complex in prokaryotes), SecG (internal membrane complex in prokaryotes) or Sec61 (internal membrane complex in eukaryotes), SecD (membrane protein), and SecF (membrane protein).
- SecB chaperone protein
- SecA ATPase
- SecY internal membrane complex in prokaryotes
- SecE internal membrane complex in prokaryotes
- SecG internal membrane complex in prokaryotes
- Sec61 internal membrane complex in eukaryotes
- SecD membrane protein
- SecF membrane complex in e protein
- TTS Type III Secretion System
- Translocase such as HrcN and any of the 20 subunits of the TTS translocases, or Sec- independent periplasmic protein translocase TatC.
- chaperones are proteins that assist the non-covalent folding or unfolding and the assembly or disassembly of other macromolecular structures, but do not occur in these structures when the structures are performing their normal biological functions having completed the processes of folding and/or assembly.
- Many chaperones are heat shock proteins, that is, proteins expressed in response to elevated temperatures or other cellular stresses.
- Hsp 70 refers to 70-kDa heat shock proteins (Hsp70s), such as DnaK, HscA (Hsc66), and HscC (Hsc62) in prokaryotes, and Hsc70, Hsp70, BiP or Grp78 (binding immunoglobulin protein), mtHsp70 or Grp75 in eukaryotic organisms, and human Hsp70 proteins, such as Hsp70, Hsp70-2, Hsp70-4, Hsp70- 4L, Hsp70-5, Hsp70-6, Hsp70-7, Hsp70-8, Hsp70-9, Hsp70-12a, Hsp70-14.
- Hsp70s heat shock proteins
- Hsp70s such as DnaK, HscA (Hsc66), and HscC (Hsc62) in prokaryotes
- Hsc70, Hsp70, BiP or Grp78 binding immunoglobul
- Hsp70 proteins are central components of the cellular network of molecular chaperones and folding catalysts. Hsp70s assist a wide range of folding processes, including the folding and assembly of newly synthesized proteins, refolding of misfolded and aggregated proteins, membrane translocation of organellar and secretory proteins, and control of the activity of regulatory protein. ATP binding and hydrolysis are essential in vitro and in vivo for the chaperone activity of Hsp70 proteins. Hsp70 chaperone families are recognized as most common remodeling enzyme together with Hsp60 chaperone families. Hsp70s and Hsp60s prevent off -pathway interactions during protein folding by providing an isolated environment for the folding protein. In contrast, the Clp/HsplOO unfolding enzymes actively direct the structural changes in their substrates. Clp/HsplOOs act on folded and assembled complexes, as well as improperly folded and aggregated proteins.
- HSP90 aids the delivery of the mitochondrial preprotein to the TOM complex in an ATP-dependent process.
- Hsp 100 (Clp family in E. coli) proteins have been studied in vivo and in vitro for their ability to target and unfold tagged and misfolded proteins. Proteins in the HsplOO/Clp family form large hexameric structures with unfoldase activity in the presence of ATP. These proteins are thought to function as chaperones by processively threading client proteins through a small 20 A (2 nm) pore, thereby giving each client protein a second chance to fold.
- HsplOO chaperones like ClpA and ClpX, associate with the double-ringed tetradecameric serine protease ClpP; instead of catalyzing the refolding of client proteins, these complexes are responsible for the targeted destruction of tagged and misfolded proteins.
- Hspl04 the HsplOO of Saccharomyces cerevisiae, is essential for the propagation of many yeast prions. Deletion of the HSP104 gene results in cells that are unable to propagate certain prions.
- the enzyme used in the working examples has the sequence:
- ClpA or Clp X may be coupled to the nanopore.
- An engineered alpha- hemolysin/ClpP fusion protein pore may be assembled to form an active heptameric protein nanopore covalently fused at its N-terminal cap domain to the ClpX-binding domain of the ClpP heptamer complex. Fusion of the ClpX- binding domain of ClpP to the top of the nanopore will enable ClpX to assemble in solution, attach to the ClpP domain, and function on the top of nanopore
- Figure 10 illustrates a fusion protein comprising the a-hemolysin pore protein subunits fused to subunits of a ClpP protein.
- the ClpX protein translocase can then non- covalently "dock" onto the ClpP subunits.
- the protein translocase is on the cis side of, and fused to, the nanopore.
- the axial pores of the translocase and the nanopore must be aligned in the correct orientation; that is, ClpX must be bound to the nanopore in such a way that as the protein substrate is captured from solution and driven through the ClpX central cavity, it then directly enters into the AHL (alpha hemolysin) upper lumen and is eventually forced through the entire nanopore (See Figure 10).
- AHL alpha hemolysin
- the ClpX hexamer naturally binds to the head domains at each opening of the tetradecameric (double heptameric rings) protease ClpP and acts as a gate that only allows tagged proteins to enter the proteolytic chamber.
- ClpX-binding domain of ClpP onto the head of AHL, it will enable ClpX to directly bind with high affinity atop the nanopore via a natural protein- protein interaction.
- Fusion protein may be done through coupled in-vitro transcription and translation using the T7-S30 expression system, used previously to express AHL fusions, and purified with Ni-NTA affinity chromatography.
- translocase is on the cis side of the device involves the use of accessory proteins.
- proteins that bind to the substrate protein are used to facilitate control of movement of the substrate protein to or though the nanopore.
- the protein present in the trans side (as in Figure 1) need not be an active translocase/unfoldase but rather another protein (for example trigger factor) that non- specifically binds to unfolded portions of polypeptides.
- Trigger factor is a ribosome-associated molecular chaperone and is the first chaperone to interact with a nascent polypeptide. It acts as a chaperone by maintaining the newly synthesized protein in an open conformation. Other chaperonins or heat shock proteins could be used.
- This trans side protein (e.g. trigger factor) would thereby sequentially capture the unfolded substrate protein as it is translocated into the trans solution by the cis side translocase/unfoldase, preventing the substrate protein from moving back into the cis side.
- the substrate protein is provided with a factor that blocks its unfolding by the unfoldase until a predetermined state is reached.
- both substrate protein and unfoldase are added to the cis side.
- Substrate proteins are tagged at one terminus with an unfoldase-binding motif (for example the ssrA tag for ClpX), a pore- targeting domain (for example a charged poly-peptide tail that will be pulled into the pore under an applied voltage), and an unfoldase-resistant protein (for example dihydrofolate reductase or barnase in presence of stabilizing ligands are resistant to unfolding by ClpX; see, Hoskins, JR et al.
- an unfoldase-binding motif for example the ssrA tag for ClpX
- a pore- targeting domain for example a charged poly-peptide tail that will be pulled into the pore under an applied voltage
- an unfoldase-resistant protein for example dihydrofolate reductase
- ClpAP and ClpXP degrade proteins with tags located in the interior of the primary sequence.
- the substrate protein therefore is protected from the unfoldase with this "blocking domain" between the its folded domain and the pore targeting and unfoldase-binding motif domains.
- the blocking domain protein (fused with the pore-targeting domain and unfoldase- targeting motif domain) may be chemically or enzymatically attached to the substrate protein post-translationally.
- the unfoldase binds to the unfoldase-binding motif and translocates along the pore-targeting domain. Translocation of the unfoldase along the tagged substrate stops once the enzyme approaches the unfoldase-resistant protein (the "blocking domain").
- the blocking domain the unfoldase-resistant protein
- unfolding and translocation of the blocking domain is initiated. It is catalyzed by the extra destabilizing forces imparted by the voltage at the pore and/or other protein translocases/unfoldases present in the trans solution that interact with the tagged substrate protein tail after capture and threading of the substrate tail through the pore. Unfolding and translocation of the entire substrate protein by the cis-bound unfoldase through the nanopore is then possible after the pore-activated unfolding of the blocking domain is catalyzed.
- blocking domain sequence strategy example sequence is as follows: N-terminus— substrate protein— blocking domain— charged tail— unfoldase-binding motif— C-terminus.
- ClpX complexes are placed in solution on the trans side of the nanopore, and the substrate protein dissolved on cis side of the nanopore will be forced to thread through the nanopore beginning at the N or C terminus (for example, voltage-driven by engineering a few charged amino acids into the protein terminus, such as 5-10 Asp, Lys or Arg residues) where the ClpX complex will capture this tagged polypeptide tail, and begin mechanically pulling/ translocating the substrate down through the nanopore.
- Native ClpX binding, unfolding, and translocation activity of tagged proteins is used to control the movement of proteins through a nanopore sensor for subsequent analysis.
- a wild type protein nanopore or other solid-state nanopore may be utilized if ClpX or another translocase such as ClpA is placed on the trans side of the device, in solution, where it is allowed to capture tagged protein tails that were threaded from the cis side through the nanopore to the trans side solution (that is, "fishing" for the ClpX). Upon capture of this tagged- tail, the ClpX complex would be able to begin mechanically pulling on the protein from across the pore, until it is eventually able to unfold and thread the entire polypeptide through the pore and into the trans side solution.
- the initial threading of the tagged-tail could be accomplished via the addition of several charged residues proximal to the tag sequence on the N or C terminus of the target protein, wherein a voltage differential would drive the charged tail through the nanopore, making it available to "fish" for ClpX.
- the protein translocase is added in solution to the trans side of the chamber; it serves to unfold the protein to be translocated by pulling it through the nanopore, which is too narrow to permit passage of the folded protein.
- the same or a different protein translocase may be located on the cis side of the nanopore for unfolding the protein.
- the method of sensing in the present method and device may involve measuring one, two, three, four or five or more characteristics of the protein.
- the one or more characteristics are preferably selected from (i) the length of the protein, (ii) the identity of the protein, (iii) the sequence of the protein, (iv) the secondary or tertiary structures of the protein and (v) whether or not the protein is modified. Any combination of (i) to (v) may be measured in accordance with the invention.
- the length of the protein may be measured using the number of interactions between the protein and the pore, and/or the dwell time of the protein as it translocates through the pore.
- the identity of the protein may be measured in a number of ways. The identity of the protein may be measured in conjunction with measurement of the sequence of the protein or without measurement of the sequence of the protein. The former is straightforward; the protein is sequenced and thereby identified. The latter may be done in several ways. For instance, the presence of a particular motif in the protein may be measured (without measuring the remaining sequence of the protein). Alternatively, the measurement of a particular electrical and/or optical signal in the method may identify the protein as coming from a particular source.
- the sequence of the protein can be determined as described herein.
- the sequence may be determined on an individual amino acid residue-by-residue basis, or may be read in blocks of amino acids, which may be mapped to known protein sequences, in a manner analogous to re-sequencing of DNA.
- the method need not resolve each individual amino acid, but rather one could just resolve "words" or
- the secondary and tertiary structures may be measured in a variety of ways. For instance, if the method involves an electrical measurement, the secondary structure (e.g. detection of an alpha helix region versus a loop region or a beta sheet region) may be measured using a change in dwell time or a change in current flowing through the pore. For characteristic (v), the presence or absence of any modification may be measured.
- the method preferably comprises determining whether or not the protein is modified by methylation phosphorylation, oxidation, by damage (e.g. misfolding or covalent modification of an amino acid), by glycosylation or with one or more labels, tags or spacers. Specific modifications will result in specific interactions with the nanopore which can be measured using the methods described below.
- the present methods and device can extract protein sequence information from the protein being translocated by analysis of the ionic current measured through the nanopore. This is partly dependent on the use of sensitive electronics such as a patch clamp amplifier, a finite state machine, and signal processing such as weighted averaging, all described below.
- the present methods involve analysis of various current states that have now been found to be associated with the transit of the protein through the nanopore and the concomitant current blockage, unblockage or modulation.
- the signal detected by enzyme-mediated protein traversal will enter a so-called “ramping state” which is characteristic of binding of the enzyme to the substrate protein, then a series of separate amplitude transitions as the protein translocates through the nanopore, followed by an open state equivalent to current through the pore prior to translocation.
- a so-called “ramping state” which is characteristic of binding of the enzyme to the substrate protein
- a series of separate amplitude transitions as the protein translocates through the nanopore, followed by an open state equivalent to current through the pore prior to translocation.
- state (iv) (Fig. 2A and 2B) presents a current pattern that can be correlated to protein structure.
- the artificial linkers used in the examples showed different current amplitudes and duration.
- RMS noise to the amino acid-dependent features of the translocated protein. This includes but is not limited to tertiary and secondary structures, amino acid sequence and post-translational modifications
- the nanopore biosensing technology is based on the blockage of ionic current that occurs when a molecule translocates through and/or interacts with a pore under an applied voltage.
- the current blockade is thus dependent upon the applied voltage and the properties of the interacting molecule (for example, charge, size).
- Time-dependent transport properties of the nanopore aperture may be measured by any suitable technique.
- the transport properties may be a function of the medium used to transport the polypeptide, solutes (for example, ions) in the liquid, the polypeptide (for example, chemical structure of the monomers), or labels on the polypeptide.
- Exemplary transport properties include current, conductance, resistance, capacitance, charge,
- the transport property is current.
- Exemplary means for detecting the current between the cis and the trans chambers have been described in WO 00/79257, U.S. Patent Nos. 6,46,594, 6,673 6,673,615,
- the electrodes may be capable of, but not limited to, detecting ionic current differences across the two chambers or electron tunneling currents across the pore aperture or channel aperture.
- the transport property is electron flow across the diameter of the aperture, which may be monitored by electrodes disposed adjacent to or abutting on the nanopore circumference. Such electrodes can be attached to an
- Axopatch 200B amplifier for amplifying a signal.
- the medium is electrically conductive. In another preferred embodiment, the medium is an aqueous solution. In another preferred embodiment, the method further comprises the steps of measuring the electrical current between the two pools; comparing the electrical current value (1 obtained at the first time the first polarity was induced with the electrical current value (I 2 ) obtained at the time the second time the first polarity was induced; and determining the difference between I and I 2 thereby obtaining a difference value ⁇ . In another preferred embodiment the method further comprises the steps of measuring the electrical current between the two pools; comparing the electrical current value (10 obtained at the first time the first polarity was induced with the electrical current value (I 2 ) obtained at a later time and determining the difference between II and I 2 thereby obtaining a difference value ⁇ .
- the method further comprises the steps of providing reagents that initiate enzyme activity; introducing the reagents to the pool comprising the polypeptide complex; and incubating the pool at a suitable temperature.
- the reagents are selected from the group consisting of an activator and a cofactor
- the subject devices typically comprise a mixed-signal semiconductor wafer, at least one electrochemical layer, the electrochemical layer comprising a semiconductor material, such as silicon dioxide or the like, wherein the semiconductor material further comprises a surface modifier, such as a hydrocarbon, wherein the electrochemical layer defines a plurality of orifices, the orifices comprising a chamber and a neck and wherein the chamber of the orifices co-localize with a first metal composition of the mixed-signal semiconductor wafer, wherein a portion of the orifice is plugged with a second metal, for example, silver, wherein the second metal is in electronic communication with the first metal, and wherein the orifice further comprises a thin film, such as a phospholipid bilayer, the thin film forming a solvent-impermeable seal at the neck of the orifice, the thin film further comprising a pore, and wherein the orifice encloses an aqueous
- the semiconductor material is selected from the group consisting of silicon dioxide (Si02), silicon oxy nitride (SiON), silicon nitride (SiN), metal oxide, and metal silicate.
- the semiconductor material is silicon dioxide.
- the surface modifier is a hydrocarbon.
- the metallization composition is selected from the group consisting of nickel, gold, copper, and aluminum.
- the metal is silver.
- the thin film is a molecular bilayer. In another preferred embodiment, the thin film is a phospholipid bilayer. In one alternative embodiment, the orifice is between 0.5 and 3 ⁇ in size.
- the orifice is between 1 and 2 ⁇ in size. In a most preferred embodiment, the orifice is between 1.25 and 1.5 ⁇ in size.
- the pore is a biological molecule. In another preferred embodiment, the biological molecule is selected from the group consisting of an ion channel, a nucleoside channel, a peptide channel, a sugar transporter, a synaptic channel, a
- the biological molecule is alpha-hemolysin.
- the pore aperture is between about 1 and 10 nm in size. In another preferred embodiment, the pore aperture is between about 1 and 4 nm in size. In a most preferred embodiment, the pore aperture is between about 1 and 2 nm in size. In an alternative most preferred embodiment the pore aperture is between about 2 and 4 nm in size.
- Biological nanopores have utility in detection of polypeptides but, due to the low current used (approximately in the tens of picoamps). Detection using high-through put of a single nanopore sequencing device may be limited to approximately 1000 amino acid residues per second. Manufacturing arrays of biological nanopores that can operate independently of each other, such as used in the manufacture of very large arrays of integrated circuits, allow a very large scale array of nanopores to perform millions of biochemical reactions and analyses in a single second.
- the pore or channel is shaped and sized having dimensions suitable for passaging a polymer.
- the pore or channel accommodates a substantial portion of the polymer.
- the polymer is a polypeptide.
- the pore or channel may also be a pore molecule or a channel molecule and comprise a biological molecule, or a synthetic modified molecule, or altered biological molecule, or a combination thereof.
- biological molecules are, for example, but not limited to, an ion channel, such as cc-hemolysin ,MspA, a nucleoside channel, a peptide channel, a sugar transporter, a synaptic channel, a
- transmembrane receptor such as GPCRs and the like, a receptor tyrosine kinase and the like, a T-cell receptor, a MHC receptor, a nuclear receptor, such as a steroid hormone receptor, a nuclear pore, synthetic variants, chimeric variants, or the like.
- the biological molecule is cc-hemolysin.
- the biological molecule is MspA (Mycobacteria smegmatis porin A).
- the pore is a solid-state pore.
- the pore or channel comprises non-enzyme biological activity.
- the pore or channel having non-enzyme biological activity can be, for example, but not limited to, proteins, peptides, antibodies, antigens, nucleic acids, peptide nucleic acids (PNAs), locked nucleic acids (LNAs), morpholinos, sugars, lipids, glycosyl phosphatidyl inositols, glycophosphoinositols, lipopolysaccharides or the like.
- the compound can have antigenic activity.
- the compound can have selective binding properties whereby the polymer binds to the compound under a particular controlled environmental condition, but not when the environmental conditions are changed. Such conditions can be, for example, but not limited to, change in [H + ], change in environmental temperature, change in stringency, change in hydrophobicity, change in hydrophilicity, or the like.
- the pore or channel further comprises a linker molecule, the linker molecule selected from the group consisting of a thiol group, a sulfide group, a phosphate group, a sulfate group, a cyano group, a piperidine group, an Fmoc group, and a Boc group.
- the compound is selected from the group consisting of a bifunctional alkyl sulfide and gold.
- the pore is sized and shaped to allow passage of an activator, wherein the activator is selected from the group consisting of ATP, NAD + , NADP + , diacylglycerol, phosphatidylserine, eicosinoids, retinoic acid, calciferol, ascorbic acid, neuropeptides, enkephalins, endorphins, 4-aminobutyrate (GABA), 5-hydroxytryptamine (5- HT), catecholamines, acetyl CoA, S-adenosylmethionine, and any other biological activator.
- the activator is selected from the group consisting of ATP, NAD + , NADP + , diacylglycerol, phosphatidylserine, eicosinoids, retinoic acid, calciferol, ascorbic acid, neuropeptides, enkephalins, endorphins, 4-aminobutyrate (GABA), 5-
- the pore is sized and shaped to allow passage of a cofactor, wherein the cofactor is selected from the group consisting of Mg 2+ , Mn 2+ , Ca 2+ , ATP, NAD + , NADP + , and any other biological cofactor.
- the array elements may be manufactured in a step-wise parallel manner, similar to the manufacture of transistors on integrated circuits. All, or most, of the similar layers of each array element are created in a sequence of single process steps that simultaneously take place on all, or most, of the array elements. There appears to be no simple way to synchronize the activities of separate molecules of biological reagents, so each element in the array should be able to act independently of the other elements. This may be accomplished by including a digital logic circuit with each single biological nanopore that implements a finite state machine that controls and senses the biochemical state of the complex off single (or multiple) molecules associated with the biological nanopore. The finite state machine allows low latency control of the complex of molecules associated with the biological nanopore and at the same time can store information gathered for retrieval at another time.
- a serial interface and addressable logic can be used to multiplex the large amount of data entering and exiting the array.
- the array elements may have a thin film or bilayer across their respective orifice.
- the capacitance of the membrane present in the nanopore as measured by the finite state machine can be used to detect the presence of non-functional array elements. If it is subsequently determined that a proportion of array elements lack a thin film or bilayer is greater when compared with a proportion that is preferred, then the step of overlaying the membrane such as TEFLON film and lipid coat can be repeated.
- An electrode for example a grounded macroscopic AgCl electrode, may be placed in contact with second solution.
- membranes such as bilayers are positioned in place across all the functionable orifices, no ion current will flow from second solution to first solution.
- a predetermined amount of pore molecule or channel molecule such as for example, alpha-hemolysin toxin or MspA, is added to second solution.
- the concentration of pore molecule or channel molecule is sufficient to form a single channel in any of the thin films or bilayers in approximately, for example, fifteen minutes.
- the time to form such channels can be for example, between one-half minute and one hour, for example, about one- half minute, one minute, two minutes, three minutes, four minutes, five minutes, seven minutes, ten minutes, fifteen minutes, twenty minutes, twenty five minutes, thirty minutes, thirty five minutes, forty minutes, forty five minutes, fifty minutes, fifty five minutes, sixty minutes, or any time therebetween.
- the time for formation can be altered by an operator by several factors or parameters, for example, increasing or decreasing the ambient or incubation temperature, increasing or decreasing the concentration of salt in second solution or first solution, placing a potential difference between the first solution and the second solution, or other methods know to those of skill in the art.
- the finite state machine can detect and/or sense formation of a single channel in its corresponding bilayer by reacting to the flow of current (ions) through the circuit, the circuit comprising the macroscopic electrode, the second solution, the single nanopore or channel molecule, first solution, and the metal electrode for any given array element.
- Formation of biological channels is a stochastic process. Once a single channel has formed in a given array element bilayer, it is preferred that the chance that a second channel so forming therein is reduced or preferably, eliminated.
- the probability of second channel insertion can be modulated with applied potential, that is, potential difference, across the bilayer.
- a finite state machine may adjust the potential on the metal electrode to decrease the possibility of second channel insertion into the same bilayer.
- a second channel may form in a given bilayer.
- the finite state machine can detect the formation of the second channel.
- a pulse of precisely controlled low pressure can force one out of two channels allowing a single channel to remain embedded in the bilayer.
- each array element may comprise a gold electrode surrounding the orifice. This gold electrode may serve to activate chemical reagents using reduction or oxidation reactions and that can act specifically at the location of a specific orifice.
- the finite state machine can be created for example using state-of-the-art commercially available 65nm process technology, for example from Taiwan Semiconductor Manufacturing Company, Taiwan).
- a 600 x 600 array of nanopores can perform 360,000 biochemical reaction and detection/sensing steps at a rate of 1000 Hz. This may enable sequencing of polynucleotides, for example, to proceed at a rate of 360 million baser per second per 1 cm x 1 cm die cut from the semiconductor wafer.
- Exemplary means for applying an electric field between the cis- and /raws-chambers are, for example, electrodes comprising an immersed anode and an immersed cathode, that are connected to a voltage source.
- Such electrodes can be made from, for example silver chloride, or any other compound having similar physical and/or chemical properties.
- a patch-clamp amplifier Molecular Devices AxoPatch 200B, regulates the applied voltage and measures the ionic current through the channel.
- the data are recorded using the Molecular Devices Digidata 1440A digitizer, sampled at 50 kHz and low-pass filtered at 5 kHz with a four-pole Bessel filter.
- One of the station uses a different patch clamp, the A-M systems Model 2400.
- Control Lo ic Hardware and Software
- the voltage control logic is programmed using a finite state machine (FSM) within the Lab VIEW 8 software.
- the FSM logic is implemented on a field-programmable gate array (FPGA) hardware system, National Instruments PCI-7831R.
- An FPGA is a reconfigurable hardware platform that permits fast measurement and voltage reaction times (1 output sample time).
- An FSM is a logic construct in which program execution is broken up into a series of individual states. Each state has a command associated with it, and transitions between states are a function of system measurements. Measurements of the pore current are processed and passed to the FSM as inputs. Changes in the FSM control logic are made as necessary, without the need to re-compile and re-route the design to run on the FPGA. This achieves a balance between speed and flexibility, by enabling the system to react to events on the order of a microsecond, while also allowing for the control logic to be reconfigured as necessary between experiments.
- the finite state machine can be used to detect and control binding of a molecule to a polymer.
- the molecule is a protein, preferably the protein is an enzyme.
- the finite state machine can also detect a polymer compound having a structural element that inhibits transposition of the polymer compound through a nanopore.
- the polymer compound comprises a peptide nucleic acid.
- the finite state machine can control binding of a molecule to a polymer at a rate of between about 5 Hz and 2000 Hz.
- the finite state machine can control binding of a molecule to a polymer at, for example, about 5 Hz, at about 10 Hz, at about 15 Hz, at about 20 Hz, at about 25 Hz, at about 30 Hz, at about 35 Hz, at about 40 Hz, at about 45 Hz, at about 50 Hz, at about 55 Hz, at about 60 Hz, at about 65 Hz, at about 70 Hz, at about 75 Hz, at about 80 Hz, at about 85 Hz, at about 90 Hz, at about 95 Hz, at about 100 Hz, at about 110 Hz, at about 120 Hz, at about 125 Hz, at about 130 Hz, at about 140 Hz, at about 150 Hz, at about 160 Hz, at about 170 Hz, at about 175 Hz, at about 180 Hz, at about 190 Hz, at about 200 Hz, at
- the finite state machine can control binding of a molecule to a polymer at a rate of between about 25 Hz and about 250 Hz. In amore preferred embodiment the finite state machine can control binding of a molecule to a polymer at a rate of between about 45 Hz and about 120 Hz. In a most preferred embodiment the finite state machine can control binding of a molecule to a polymer at a rate of about 50 Hz. Moving Average Filter
- the FPGA samples the ionic current and computes a windowed mean amplitude, using a window size of 0.75 msec. If the mean enters a chosen threshold range, the FPGA detects entry and continues to monitor the mean, re-checking the threshold every 0.2 msec. If the mean remains within the threshold range for four consecutive checks, the FSM logic diagnoses the blockade as an event type known to be consistent with the chosen threshold.
- the expected time delay between the start of an event and diagnosis of an event is 1.35 msec; 0.75 msec for the windowed mean to first enter the threshold, and 0.6 msec for three more confirmed tests.
- the diagnosis time ranges from 1.1 to 2.5 msec.
- the mean filter was implemented in our invention's initial demonstration
- EWMA filter may be used to replace the mean filter.
- the EWMA filter represents a digital implementation of an analog RC filter commonly used for signal smoothing in electrical engineering applications.
- the filter calculates a moving average that places exponentially less significance on past samples and allows the filtered signal to better track the real signal.
- the expected time delay between the start of an event and diagnosis of an event is 0.7 msec; 0.1 msec for the EWMA to first enter the threshold, and 0.6 msec for three more confirmed tests. More rigorous evaluation of EWMA detection times will be part of our ongoing work.
- the nanopore system can be setup in a 0.3 mM KC1 solution.
- a patch-clamp amplifier, Molecular Devices AxoPatch 200B regulates the applied voltage and measures the ionic current through the channel.
- the data are recorded using the Molecular Devices Digidata 1440A digitizer, sampled at 50 kHz and low-pass filtered at 5 kHz with a four-pole Bessel filter.
- the voltage control logic is programmed using a FSM within the Lab VIEW 8 software.
- the FSM logic is implemented on a field-programmable gate array (FPGA) hardware system, National Instruments PCT7831R.
- An FPGA is a reconfigurable hardware platform that permits fast measurement and voltage reaction times (1 ⁇ && ⁇ output sample time).
- An FSM is a logic construct where program execution is broken up into a series of individual states. Each state has a command associated with it, and transitions between states are a function of system measurements. Measurements of the pore current are processed and passed to the FSM as inputs. Changes in the FSM control logic are made as necessary, without the need to re-compile and reroute the design to run on the FPGA. This achieves a balance between speed and flexibility, by enabling the system to react to events on the order of a microsecond, while also allowing for the control logic to be reconfigured as necessary between experiments.
- Applications and/or uses of the invention disclosed herein may include, but not be limited to the following: 1). Assay of protein-nucleic acid complexes in mRNA, rRNA, and DNA. 2). Assay of the presence of microbe or viral content in food and environmental samples via peptide analysis. 3). Identification of microbe or viral content in food and environmental samples via peptide analysis. 4). Identification of pathologies via peptide analysis in plants, human, microbes, and animals. 5). Assay of peptides in medical diagnosis. 6). Forensic assays.
- the present nanopore device can be used to monitor the turnover of enzymes such as proteases, kinases, and phosphatases, which have important applications in cell proliferation.
- the present nanopore device can function as a biosensor to monitor the interaction between soluble substances such as enzyme substrates or signaling molecules.
- soluble substances such as enzyme substrates or signaling molecules.
- Examples include blood components such as glucose, uric acid and urea, hormones such as steroids and cytokines, and pharmaceutical agents that exert their function by binding to receptor molecules.
- the present nanopore device can monitor in real time the function of important biological structures such as ribosomes, and perform this operation with a single functional unit.
- the present methods and devices may also be used to detect and quantify altered protein expression, absence/presence versus excess, expression of proteins or to monitor protein levels during therapeutic intervention.
- the amount of protein in a given sample may be estimated using an array of nanopore devices according to the present invention.
- Polypeptides or proteins to be translocated can also be utilized as markers of treatment efficacy against the diseases noted above and other brain disorders, conditions, and diseases over a period ranging from several days to months. Qualitative or quantitative methods for this comparison are well known in the art.
- polypeptides, fragments, oligopeptides, and PNAs that may be translocated by the present system may be used to detect and quantify altered protein expression
- Conditions, diseases or disorders associated with altered expression include idiopathic pulmonary arterial hypertension, secondary pulmonary hypertension, a cell proliferative disorder, particularly anaplastic oligodendroglioma, astrocytoma,
- oligoastrocytoma oligoastrocytoma, glioblastoma, meningioma, ganglioneuroma, neuronal neoplasm, multiple sclerosis, Huntington's disease, breast adenocarcinoma, prostate adenocarcinoma, stomach adenocarcinoma, metastasizing neuroendocrine carcinoma, nonproliferative fibrocystic and proliferative fibrocystic breast disease, gallbladder cholecystitis and cholelithiasis, osteoarthritis, and rheumatoid arthritis; acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, benign prostatic hyperplasia, bronchitis, Chediak-Higashi syndrome, cholec
- endometriosis a disruption of the estrous cycle, a disruption of the menstrual cycle, polycystic ovary syndrome, ovarian hyperstimulation syndrome, an endometrial or ovarian tumor, a uterine fibroid, autoimmune disorders, an ectopic pregnancy, and terato genesis; cancer of the breast, fibrocystic breast disease, and galactorrhea; a disruption of
- spermatogenesis abnormal sperm physiology, benign prostatic hyperplasia, prostatitis, Peyronie's disease, impotence, gynecomastia; actinic keratosis, arteriosclerosis,
- MCTD mixed connective tissue disease
- myelofibrosis paroxysmal
- nocturnal hemoglobinuria polycythemia vera
- primary thrombocythemia complications of cancer
- cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, tera
- the polynucleotide of the invention in another aspect, the polynucleotide of the invention.
- the polypeptides, fragments, oligopeptides, and PNAs, or fragments thereof may be used to detect and quantify altered protein expression, absence/presence versus excess, expression of proteins or to monitor protein levels during therapeutic intervention.
- Disorders associated with altered expression include akathesia, Alzheimer's disease, amnesia, amyotrophic lateral sclerosis, ataxias, bipolar disorder, catatonia, cerebral palsy, cerebrovascular disease Creutzfeldt-Jakob disease, dementia, depression, Down's syndrome, tardive dyskinesia, dystonias, epilepsy, Huntington's disease, multiple sclerosis, muscular dystrophy, neuralgias, neurofibromatosis, neuropathies, Parkinson's disease, Pick's disease, retinitis pigmentosa, schizophrenia, seasonal affective disorder, senile dementia, stroke, Tourette's syndrome and cancers including adenocarcinomas, melanomas, and
- polypeptides or proteins can also be utilized as markers of treatment efficacy against the diseases noted above and other brain disorders, conditions, and diseases over a period ranging from several days to months.
- Qualitative or quantitative methods for this comparison are well known in the art.
- the polypeptide or peptide may be labeled by standard methods and added to a biological sample from a patient under conditions for the formation of
- hybridization complexes After an incubation period, the sample is washed and the amount of label (or signal) is quantified and compared with a standard value. If the amount of label in the patient sample is significantly altered in comparison to the standard value, then the presence of the associated condition, disease or disorder is indicated.
- a normal or standard expression profile is established. This may be accomplished by combining a biological sample taken from normal subjects, either animal or human, with a peptide tag under conditions for hybridization or
- Standard hybridization may be quantified by comparing the values obtained using normal subjects with values from an experiment in which a known amount of a substantially purified target sequence is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a particular condition, disease, or disorder. Deviation from standard values toward those associated with a particular condition is used to diagnose that condition.
- Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies and in clinical trial or to monitor the treatment of an individual patient. Once the presence of a condition is established and a treatment protocol is initiated, diagnostic assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate the level that is observed in a normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.
- Example 1 Construction of a nanopore device for monitoring protein translocation
- the nanopore device of this example is diagrammed in Figure 1A, which represents the set up used.
- a nanopore sensor was prepared with a single AHL pore embedded in a lipid bilayer separating two Teflon® PTFE polymer wells each containing 100 ⁇ of 0.2 M KC1 solution (30°C). Voltage is applied between the wells (trans side +180 mV), causing ionic current flow through the channel. Current diminishes in the presence of a captured protein molecule.
- lysis buffer 50 mM NaH2P04 pH 8, 300 mM NaCl, 100 mM KC1, 20 mM imidazole, 10% glycerol, 10 mM BME
- lysis buffer 50 mM NaH2P04 pH 8, 300 mM NaCl, 100 mM KC1, 20 mM imidazole, 10% glycerol, 10 mM BME
- the protein was purified on a Ni2+ -NTA affinity column (Thermo) and an Uno-Q anion exchange column (Bio-Rad). Both cis compartment and trans compartment are filled with 100 ⁇ of a 200 mM KC1 buffer optimized for ClpX function. This buffer was supplemented with 5 mM ATP as indicated.
- a patch-clamp amplifier (Axopatch 200B, Molecular Devices) applied a constant 180 mV potential between two Ag/AgCl electrodes (trans side +) and recorded ionic current through the nanopore as a function of time. Substrate proteins were added to the cis solution at ⁇ 1 ⁇ final concentration, while -100 nM ClpX was present in the trans solution.
- a constant 180 mV potential was applied across the bilayer and ionic current was measured through the nanopore between Ag/AgCl electrodes in series with an integrating patch clamp amplifier (Axopatch 200B, Molecular Devices) in voltage clamp mode.
- Experimental conditions were prepared by the daily preparation of PD/ATP 5 mM and PD/ATP 4 mM.
- ClpX was diluted 1: 10 in PD/ATP 5 mM for a final concentration of 30-100 nM ClpX in 4.5 mM ATP final.
- ClpX solution was used to fill the entire system before isolation of a single AHL nanopore.
- the cis well was perfused with ⁇ 6 mL PD/ATP 4 mM.
- Experiments were conducted at 30 °C with 1-2 ⁇ substrate added to the cis well.
- Protein substrate capture events were ejected with reserve polarity due to pore clogs or after a predetermined duration.
- Voltage-induced translocations were frequently ejected to prevent clogging and to increase the efficiency of data collection.
- a single nanopore experiment is defined as the time during which ionic current data were acquired from one AHL nanopore in an intact bilayer before termination by bilayer rupture, loss of channel conductance or completion of a preset number of translocation events.
- Example 2 Engineering protein SI, S2-35 and S2-148 for translocation
- FIG. 1C shows (i) SI, a protein bearing a single N-terminal Smt3-domain coupled to a 65- amino-acid-long charged flexible segment capped at its carboxy-terminus with the 11 amino acid ClpX-targeting domain (ssrA tag); (ii) S2-35, similar to SI but appended at its N- terminus by a 35 amino acid linker and a second Smt3 domain; (iii) S2-148, identical to S2- 35 except for an extended 148 amino acid linker between the Smt3 domains.
- Smt3 is comprised of -100 amino acids arranged into four ⁇ -strands and a single cc- helix.
- SI substrate protein SI
- GGSSGGSGGSGSSGDGGSSGGSGGSGSSGDGGSSGGSGGDGSSGDGGSDGDSDGSD GDGDSDGDDAANDENYALAA SEQ ID NO: 1
- PCR polymerase chain reaction
- pET-SUMO vector Invitrogen
- the 76 amino acid tail contained about 10 negatively charged residues and the 11 amino acid Clpx binding domain ssrA.
- the engineered Smt3 protein, SI was modified in two ways, 1) It was appended with a 65-amino-acid-long glycine/serine tail including 13 interspersed negatively charged aspartate residues (SEQ ID NO: 6). This unstructured polyanion was designed to promote capture and retention of SI in the electric field across the nanopore. Based on its crystal structure 13 , the Smt3 folded domain is predicted to sit on top of the AHL vestibule (Fig. IB). 2) The appended polyanion was capped at its C-terminus with the ssrA tag, an 11 amino acid ClpX-targeting motif 14 . This ssrA peptide tag allowed ClpX to specifically bind to the C-terminus of the protein when it threaded through the pore into the trans compartment.
- S2-35 (SEQ ID NO:5) was constructed by PCR-based addition of DNA encoding the 35 amino acid linker (GGSGSGGSGSGGSGSQNEYRSGGSGSGGSGSGGSG) (SEQ ID NO: 2) to the 5' end of the SI Smt-3 sequence.
- This linker- modified SI gene was then cloned into pE-SUMO vector (LifeSensors) at the Bsal site, fusing the added linker and SI sequence to the 3' end of the pE-SUMO Smt3 sequence.
- FIG. 2A shows the ionic current traces during SI translocation, (i) Open channel current through the AHL nanopore under standard conditions (-34 2 pA, RMS noise 1.2 -t 0.1 pA). (ii) Capture of the SI substrate. Upon protein capture, the ionic current drops to -14 pA (-0.7 pA RMS noise), (iii) ClpX-mediated ramping state. The ionic current decreases to below 10 pA and is characterized by one or more gradual amplitude transitions.
- ClpX served as a molecular machine that used chemical energy derived from ATP hydrolysis to pull the S 1 protein through the nanopore. This process was intermittently assisted by electrical force as charged amino acids entered the pore electric field.
- Figure 2B illustrates the working model of ClpX-mediated translocation of SI.
- Cartoons i-v correspond to ionic current states i-v in panel a. Proposed steps in this process are diagrammed in Figure 2B: i) open channel; ii) Protein SI capture by the pore with the Stm3 segment perched above the vestibule with the slender, charged polypeptide tail segment extended into the pore lumen, and the ssrA tag in the trans compartment.
- ClpX is not bound to SI or, alternatively, has bound but is still distant from the pore; iii) ClpX advances along the SI strand toward the trans-side orifice of the AHL pore until it makes contact.
- Ionic current decreases due to proximity of ClpX to the pore; iv) under combined force exerted by ClpX and the pore electric field, the Stm3 structure atop the pore is sequentially denatured thus allowing the polypeptide to advance relative to the nanopore. In this state, the ionic current has decreased because larger amino acids (or Smt3 secondary structures) have entered the pore lumen. This ionic current state persists until the SI protein is completely pulled into the trans compartment resulting in a return to the open channel current v.
- Figure 2C shows the ionic current traces during protein S2-35 translocation.
- Open channel current state i
- States ii-iv are identical to states ii-iv in panel a.
- the first four states (Fig.
- ionic current state v This dependence of ionic current on protein structure is consistent with ClpX-driven protein translocation through the nanopore.
- ionic current state v we re-examined ionic current state v observed during S2-35 translocation. This state is consistent with movement of the 35 amino acid linker through the nanopore based on two observations: 1) its average ionic current is measurably higher than surrounding states (Fig. 2C) as expected for an amino acid sequence with few bulky side chains; and 2) in the time domain, ionic current state v occurs between Smt3-dependent ionic current states iv and vi as expected given its position along the S2-35 primary sequence (Fig 1C, ii and related sequences).
- this ionic current state corresponds to translocation of the 148 amino acid linker. Its amplitude is ⁇ 3 pA higher than the S2-35 linker amplitude ( ⁇ 9 pA), and it has a median duration -2.5 fold longer than the comparable S2-35 state v.
- Figure 3C shows state v translocation dwell times for S2-148 translocation events.
- the black bars represent dwell times for events that included ramping state iii (ClpX- driven).
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Sustainable Development (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Enzymes And Modification Thereof (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2864824A CA2864824C (en) | 2012-02-16 | 2013-02-15 | Nanopore sensor for enzyme-mediated protein translocation |
KR1020147025764A KR102066758B1 (en) | 2012-02-16 | 2013-02-15 | Nanopore sensor for enzyme-mediated protein translocation |
DK13749423.3T DK2814939T3 (en) | 2012-02-16 | 2013-02-15 | Nanoporesensor for enzyme-mediated protein translocation |
BR112014020255-9A BR112014020255B1 (en) | 2012-02-16 | 2013-02-15 | APPLIANCE, SYSTEM AND METHOD FOR TRANSPORTING PROTEIN THROUGH NANOPORO |
CN201380019821.3A CN104619854B (en) | 2012-02-16 | 2013-02-15 | Nanopore sensor for the albumen primes hift that enzyme mediates |
AU2013221356A AU2013221356B2 (en) | 2012-02-16 | 2013-02-15 | Nanopore sensor for enzyme-mediated protein translocation |
JP2014557827A JP6312607B2 (en) | 2012-02-16 | 2013-02-15 | Nanopore sensors for enzyme-mediated protein translocation |
EP13749423.3A EP2814939B1 (en) | 2012-02-16 | 2013-02-15 | Nanopore sensor for enzyme-mediated protein translocation |
US14/378,448 US11339365B2 (en) | 2012-02-16 | 2013-02-15 | Nanopore sensor for enzyme-mediated protein translocation |
US17/745,399 US20220396758A1 (en) | 2012-02-16 | 2022-05-16 | Nanopore sensor for enzyme-mediated protein translocation |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261599754P | 2012-02-16 | 2012-02-16 | |
US61/599,754 | 2012-02-16 | ||
US201261713163P | 2012-10-12 | 2012-10-12 | |
US61/713,163 | 2012-10-12 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/378,448 A-371-Of-International US11339365B2 (en) | 2012-02-16 | 2013-02-15 | Nanopore sensor for enzyme-mediated protein translocation |
US17/745,399 Continuation US20220396758A1 (en) | 2012-02-16 | 2022-05-16 | Nanopore sensor for enzyme-mediated protein translocation |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013123379A2 true WO2013123379A2 (en) | 2013-08-22 |
WO2013123379A3 WO2013123379A3 (en) | 2015-03-12 |
Family
ID=48984893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/026414 WO2013123379A2 (en) | 2012-02-16 | 2013-02-15 | Nanopore sensor for enzyme-mediated protein translocation |
Country Status (10)
Country | Link |
---|---|
US (2) | US11339365B2 (en) |
EP (1) | EP2814939B1 (en) |
JP (2) | JP6312607B2 (en) |
KR (1) | KR102066758B1 (en) |
CN (1) | CN104619854B (en) |
AU (1) | AU2013221356B2 (en) |
BR (1) | BR112014020255B1 (en) |
CA (1) | CA2864824C (en) |
DK (1) | DK2814939T3 (en) |
WO (1) | WO2013123379A2 (en) |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015040423A1 (en) * | 2013-09-23 | 2015-03-26 | Isis Innovation Limited | Method |
WO2015127387A1 (en) * | 2014-02-21 | 2015-08-27 | Northeastern University | Fluorescence-based analysis of biopolymers using nanopores |
US9274430B2 (en) | 2012-10-10 | 2016-03-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Systems and devices for molecule sensing and method of manufacturing thereof |
US20160194698A1 (en) * | 2014-12-16 | 2016-07-07 | Arizona Board Of Regents On Behalf Of Arizona State University | Systems, apparatuses and methods for reading polymer sequence |
WO2016127007A3 (en) * | 2015-02-05 | 2016-10-06 | President And Fellows Of Harvard College | Nanopore sensor including fluidic passage |
US9952198B2 (en) | 2013-03-05 | 2018-04-24 | Arizona Board Of Regents On Behalf Of Arizona State University | Translocation of a polymer through a nanopore |
US10131943B2 (en) | 2012-12-19 | 2018-11-20 | Oxford Nanopore Technologies Ltd. | Analysis of a polynucleotide via a nanopore system |
US10336713B2 (en) | 2014-02-27 | 2019-07-02 | Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University | Triazole-based reader molecules and methods for synthesizing and use thereof |
US10596523B2 (en) | 2015-05-20 | 2020-03-24 | Oxford Nanopore Inc. | Methods and apparatus for forming apertures in a solid state membrane using dielectric breakdown |
US10689697B2 (en) | 2014-10-16 | 2020-06-23 | Oxford Nanopore Technologies Ltd. | Analysis of a polymer |
WO2020183172A1 (en) | 2019-03-12 | 2020-09-17 | Oxford Nanopore Technologies Inc. | Nanopore sensing device and methods of operation and of forming it |
NL2023062B1 (en) * | 2019-05-03 | 2020-11-30 | Univ Delft Tech | Protein current trace signal acquisition using a nanopore |
WO2021078971A2 (en) | 2019-10-25 | 2021-04-29 | Oxford Nanopore Technologies Limited | Improved nanopore sensing device, components and method of manufacture |
WO2021111125A1 (en) | 2019-12-02 | 2021-06-10 | Oxford Nanopore Technologies Limited | Method of characterising a target polypeptide using a nanopore |
WO2021133168A1 (en) | 2019-12-24 | 2021-07-01 | Technische Universiteit Delft | Protein and peptide fingerprinting and sequencing by nanopore translocation of peptide-oligonucleotide complexes |
WO2021255414A1 (en) | 2020-06-17 | 2021-12-23 | Oxford Nanopore Technologies Limited | Nanopore support structure and manufacture thereof |
WO2022013551A1 (en) | 2020-07-17 | 2022-01-20 | Oxford Nanopore Technologies Limited | Nanopore sensing device |
WO2022020461A1 (en) | 2020-07-22 | 2022-01-27 | Oxford Nanopore Technologies Inc. | Solid state nanopore formation |
US20220308001A1 (en) * | 2021-03-25 | 2022-09-29 | The Regents Of The University Of California | Apparatus and method for single cell discrimination |
US11561216B2 (en) | 2012-02-13 | 2023-01-24 | Oxford Nanopore Technologies Plc | Apparatus for supporting an array of layers of amphiphilic molecules and method of forming an array of layers of amphiphilic molecules |
WO2023026056A1 (en) | 2021-08-26 | 2023-03-02 | Oxford Nanopore Technologies Plc | Nanopore |
US11596940B2 (en) | 2016-07-06 | 2023-03-07 | Oxford Nanopore Technologies Plc | Microfluidic device |
US11644437B2 (en) | 2011-04-04 | 2023-05-09 | President And Fellows Of Harvard College | Nanopore sensing by local electrical potential measurement |
WO2023118891A1 (en) | 2021-12-23 | 2023-06-29 | Oxford Nanopore Technologies Plc | Method of characterising polypeptides using a nanopore |
EP4058549A4 (en) * | 2019-11-15 | 2023-12-27 | Machine Bio Inc. | Methods and systems for generating biological molecules |
US11959906B2 (en) | 2012-02-16 | 2024-04-16 | Oxford Nanopore Technologies Plc | Analysis of measurements of a polymer |
WO2024091124A1 (en) | 2022-10-28 | 2024-05-02 | Rijksuniversiteit Groningen | Nanopore-based analysis of proteins |
WO2024094986A1 (en) | 2022-10-31 | 2024-05-10 | Oxford Nanopore Technologies Plc | Method |
WO2024100270A1 (en) | 2022-11-11 | 2024-05-16 | Oxford Nanopore Technologies Plc | Novel pore monomers and pores |
US12042790B2 (en) | 2016-11-24 | 2024-07-23 | Oxford Nanopore Technologies Plc | Apparatus and methods for controlling insertion of a membrane channel into a membrane |
WO2024165853A1 (en) | 2023-02-07 | 2024-08-15 | Oxford University Innovation Limited | Method of characterising a peptide, polypeptide or protein using a nanopore |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201700745XA (en) * | 2014-07-31 | 2017-02-27 | Illumina Inc | Hybrid nanopore sensors |
US10126262B2 (en) * | 2015-09-24 | 2018-11-13 | Genia Technologies, Inc. | Differential output of analog memories storing nanopore measurement samples |
CN106443008A (en) * | 2016-08-31 | 2017-02-22 | 中国科学院重庆绿色智能技术研究院 | HIV-1 protease detection method based on solid state nanopore |
JP7362112B2 (en) * | 2017-06-29 | 2023-10-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Deterministic step of polymer through nanopore |
US11567061B2 (en) * | 2017-07-17 | 2023-01-31 | President And Fellows Of Harvard College | Nanopore-matched protein shuttle for molecular characterization |
EP3700670B1 (en) * | 2017-10-23 | 2023-11-29 | F. Hoffmann-La Roche AG | Removing and reinserting protein nanopores in a membrane using osmotic imbalance |
CN108226249B (en) * | 2018-01-09 | 2021-02-26 | 深圳市梅丽纳米孔科技有限公司 | Disposable nanopore biosensor and manufacturing method thereof |
CN112534063A (en) | 2018-05-22 | 2021-03-19 | 安序源有限公司 | Methods, systems, and compositions for nucleic acid sequencing |
EP3853262A4 (en) * | 2018-09-19 | 2022-03-30 | Conagen Inc. | Controllable protein degradation via engineering degradation tag variants in corynebacterium host cells |
US20210340192A1 (en) * | 2018-10-05 | 2021-11-04 | University Of Washington | Reporter constructs for nanopore-based detection of biological activity |
CN113260449B (en) * | 2018-12-11 | 2023-09-29 | 豪夫迈·罗氏有限公司 | Systems and methods for self-limiting protein pore insertion in membranes |
CN112147185B (en) * | 2019-06-29 | 2022-07-01 | 清华大学 | Method for controlling speed of polypeptide passing through nanopore and application of method |
CN110554079A (en) * | 2019-09-26 | 2019-12-10 | 中国科学院重庆绿色智能技术研究院 | Antibody single molecule detection system and method based on nanochannel |
WO2021208936A1 (en) * | 2020-04-14 | 2021-10-21 | 成都今是科技有限公司 | Nanopore preparation and detection method and detection apparatus thereof |
JP7450509B2 (en) | 2020-09-28 | 2024-03-15 | 日立建機株式会社 | wheeled work vehicle |
US11994508B2 (en) * | 2020-12-23 | 2024-05-28 | Northeastern University | Method and system for linearization and translocation of single protein molecules through nanopores |
WO2024138570A1 (en) * | 2022-12-29 | 2024-07-04 | 深圳华大生命科学研究院 | Biological nanopore sensor, preparation method therefor, and use thereof |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5795782A (en) | 1995-03-17 | 1998-08-18 | President & Fellows Of Harvard College | Characterization of individual polymer molecules based on monomer-interface interactions |
WO2000028312A1 (en) | 1998-11-06 | 2000-05-18 | The Regents Of The University Of California | A miniature support for thin films containing single channels or nanopores and methods for using same |
WO2000028132A1 (en) | 1998-11-05 | 2000-05-18 | Forbo International S.A. | Floor covering material and method for its production |
WO2000079257A1 (en) | 1999-06-22 | 2000-12-28 | President And Fellows Of Harvard College | Molecular and atomic scale evaluation of biopolymers |
US6362002B1 (en) | 1995-03-17 | 2002-03-26 | President And Fellows Of Harvard College | Characterization of individual polymer molecules based on monomer-interface interactions |
US6428959B1 (en) | 1999-09-07 | 2002-08-06 | The Regents Of The University Of California | Methods of determining the presence of double stranded nucleic acids in a sample |
US6464842B1 (en) | 1999-06-22 | 2002-10-15 | President And Fellows Of Harvard College | Control of solid state dimensional features |
US20030104428A1 (en) | 2001-06-21 | 2003-06-05 | President And Fellows Of Harvard College | Method for characterization of nucleic acid molecules |
US20040121525A1 (en) | 2002-12-21 | 2004-06-24 | Chopra Nasreen G. | System with nano-scale conductor and nano-opening |
WO2005124888A1 (en) | 2004-06-08 | 2005-12-29 | President And Fellows Of Harvard College | Suspended carbon nanotube field effect transistor |
WO2009077734A2 (en) | 2007-12-19 | 2009-06-25 | Oxford Nanopore Technologies Limited | Formation of layers of amphiphilic molecules |
US20090280535A1 (en) | 2008-05-06 | 2009-11-12 | Academia Sinica | SUMO Fusion Protein Expression System for Producing Native Proteins |
WO2010122293A1 (en) | 2009-04-20 | 2010-10-28 | Oxford Nanopore Technologies Limited | Lipid bilayer sensor array |
WO2011067559A1 (en) | 2009-12-01 | 2011-06-09 | Oxford Nanopore Technologies Limited | Biochemical analysis instrument |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002239284A1 (en) | 2000-11-27 | 2002-06-03 | The Regents Of The University Of California | Methods and devices for characterizing duplex nucleic acid molecules |
US8278055B2 (en) | 2002-05-01 | 2012-10-02 | Intel Corporation | Methods and device for analyte characterization |
WO2005017025A2 (en) * | 2003-08-15 | 2005-02-24 | The President And Fellows Of Harvard College | Study of polymer molecules and conformations with a nanopore |
WO2006028508A2 (en) | 2004-03-23 | 2006-03-16 | President And Fellows Of Harvard College | Methods and apparatus for characterizing polynucleotides |
DE102005013608A1 (en) * | 2005-03-24 | 2006-09-28 | Westfälische Wilhelms-Universität Münster | Apparatus and method for cell-free analytical and preparative protein synthesis |
JP5646987B2 (en) | 2007-04-04 | 2014-12-24 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Compositions, devices, systems, and methods for using nanopores |
GB0820927D0 (en) * | 2008-11-14 | 2008-12-24 | Isis Innovation | Method |
WO2010082860A1 (en) * | 2009-01-19 | 2010-07-22 | Instituto De Biologia Experimental E Tecnologia (Ibet) | Method and device for nanopore based single-molecule protein/ protein interaction detection |
GB0905140D0 (en) * | 2009-03-25 | 2009-05-06 | Isis Innovation | Method |
WO2010141468A1 (en) | 2009-06-01 | 2010-12-09 | Way Jeffrey C | Methods and molecules for yield improvement involving metabolic engineering |
US9605307B2 (en) * | 2010-02-08 | 2017-03-28 | Genia Technologies, Inc. | Systems and methods for forming a nanopore in a lipid bilayer |
EP2588613A4 (en) * | 2010-06-30 | 2013-12-04 | Univ Syracuse | Bioengineered protein pores |
-
2013
- 2013-02-15 JP JP2014557827A patent/JP6312607B2/en active Active
- 2013-02-15 EP EP13749423.3A patent/EP2814939B1/en active Active
- 2013-02-15 AU AU2013221356A patent/AU2013221356B2/en active Active
- 2013-02-15 BR BR112014020255-9A patent/BR112014020255B1/en active IP Right Grant
- 2013-02-15 US US14/378,448 patent/US11339365B2/en active Active
- 2013-02-15 CA CA2864824A patent/CA2864824C/en active Active
- 2013-02-15 KR KR1020147025764A patent/KR102066758B1/en active IP Right Grant
- 2013-02-15 CN CN201380019821.3A patent/CN104619854B/en active Active
- 2013-02-15 DK DK13749423.3T patent/DK2814939T3/en active
- 2013-02-15 WO PCT/US2013/026414 patent/WO2013123379A2/en active Application Filing
-
2017
- 2017-12-08 JP JP2017236383A patent/JP6594944B2/en active Active
-
2022
- 2022-05-16 US US17/745,399 patent/US20220396758A1/en active Pending
Patent Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6673615B2 (en) | 1995-03-17 | 2004-01-06 | President And Fellows Of Harvard College | Characterization of individual polymer molecules based on monomer-interface interactions |
US6015714A (en) | 1995-03-17 | 2000-01-18 | The United States Of America As Represented By The Secretary Of Commerce | Characterization of individual polymer molecules based on monomer-interface interactions |
US5795782A (en) | 1995-03-17 | 1998-08-18 | President & Fellows Of Harvard College | Characterization of individual polymer molecules based on monomer-interface interactions |
US6362002B1 (en) | 1995-03-17 | 2002-03-26 | President And Fellows Of Harvard College | Characterization of individual polymer molecules based on monomer-interface interactions |
WO2000028132A1 (en) | 1998-11-05 | 2000-05-18 | Forbo International S.A. | Floor covering material and method for its production |
WO2000028312A1 (en) | 1998-11-06 | 2000-05-18 | The Regents Of The University Of California | A miniature support for thin films containing single channels or nanopores and methods for using same |
US6267872B1 (en) | 1998-11-06 | 2001-07-31 | The Regents Of The University Of California | Miniature support for thin films containing single channels or nanopores and methods for using same |
WO2000079257A1 (en) | 1999-06-22 | 2000-12-28 | President And Fellows Of Harvard College | Molecular and atomic scale evaluation of biopolymers |
US6464842B1 (en) | 1999-06-22 | 2002-10-15 | President And Fellows Of Harvard College | Control of solid state dimensional features |
US6627067B1 (en) | 1999-06-22 | 2003-09-30 | President And Fellows Of Harvard College | Molecular and atomic scale evaluation of biopolymers |
US6617113B2 (en) | 1999-09-07 | 2003-09-09 | The Regents Of The University Of California | Methods of determining the presence of double stranded nucleic acids in a sample |
US6428959B1 (en) | 1999-09-07 | 2002-08-06 | The Regents Of The University Of California | Methods of determining the presence of double stranded nucleic acids in a sample |
US20030104428A1 (en) | 2001-06-21 | 2003-06-05 | President And Fellows Of Harvard College | Method for characterization of nucleic acid molecules |
US20040121525A1 (en) | 2002-12-21 | 2004-06-24 | Chopra Nasreen G. | System with nano-scale conductor and nano-opening |
WO2005124888A1 (en) | 2004-06-08 | 2005-12-29 | President And Fellows Of Harvard College | Suspended carbon nanotube field effect transistor |
WO2009077734A2 (en) | 2007-12-19 | 2009-06-25 | Oxford Nanopore Technologies Limited | Formation of layers of amphiphilic molecules |
US20090280535A1 (en) | 2008-05-06 | 2009-11-12 | Academia Sinica | SUMO Fusion Protein Expression System for Producing Native Proteins |
WO2010122293A1 (en) | 2009-04-20 | 2010-10-28 | Oxford Nanopore Technologies Limited | Lipid bilayer sensor array |
WO2011067559A1 (en) | 2009-12-01 | 2011-06-09 | Oxford Nanopore Technologies Limited | Biochemical analysis instrument |
Non-Patent Citations (21)
Title |
---|
BOCHTLER ET AL.: "The structures of HslU and the ATP-dependent protease HsIU-HsIV", NATURE, vol. 403, no. 6771, 2000, pages 800 - 805 |
CHERF, G.M.; LIEBERMAN, K.R.; RASHID, HYTHAM, R.; LAM, C.E.; KARPLUS, K.; AKESON, M.: "Automated ''Forward and reverse ratcheting of DNA in a nanopore at 5-A precision", NAT. BIOTECHNOL., vol. 30, 2012, pages 344 - 348, XP002750350, DOI: doi:10.1038/nbt.2147 |
CHURCH, G.M.; DEAMER, D.W.; BRANTON, D.; BALDARELLI, R.; KASIANOWICZ, J., CHARACTERIZATION OF INDIVIDUAL POLYMER MOLECULES BASED ON MONOMER-INTERFACE INTERACTION |
GONZALEZ-PEREZ ET AL., LANGMUIR, vol. 25, 2009, pages 10447 - 10450 |
HALLAM, K.: "Oxford nanopore to sell tiny DNA sequencer", BLOOMBERG, 17 February 2012 (2012-02-17) |
HAYDEN, E.: "Nanopore genome sequencer makes its debut", NATURE, 17 February 2012 (2012-02-17) |
HOSKINS, JR ET AL.: "ClpAP and ClpXP degrade proteins with tags located in the interior of the primary sequence", PNAS, vol. 99, no. 17, 20 August 2002 (2002-08-20), pages 11037 - 11042 |
IVANOV AP ET AL., NANO LETT., vol. 11, no. 1, 12 January 2011 (2011-01-12), pages 279 - 85 |
LIEBERMAN KR ET AL., J AM CHEM SOC., vol. 132, no. 50, 2010, pages 17961 - 72 |
MAILLARD ET AL.: "ClpX(P) generates mechanical force to unfold and translocate its protein substrates", CELL, vol. 145, 29 April 2011 (2011-04-29), pages 459 - 4669 |
MANRAO ET AL.: "DNA at single-nucleotide resolution with a mutant MspA nanopore and phi29 DNA polymerase", NAT. BIOTECHNOL., vol. 30, 2012, pages 349 - 353, XP055028414, DOI: doi:10.1038/nbt.2171 |
MARTIN ET AL.: "Rebuilt AAA+ Motors reveal operating principles for ATP-fuelled machines", NATURE, vol. 437, 2005, pages 1115 - 1120 |
MERSTORF ET AL.: "Wild type, mutant protein unfolding and phase transition detected by single-nanopore recording", ACS CHEM. BIOL., vol. 7, 2012, pages 652 - 658, XP055362278, DOI: doi:10.1021/cb2004737 |
MOHAMMAD ET AL.: "Controlling a single protein in a nanopore through electrostatic traps", J. AM. CHEM. SOC., vol. 130, 2008, pages 4081 - 4088, XP055054403, DOI: doi:10.1021/ja710787a |
OGURA ET AL.: "AAA+ superfamily ATPases'' common structure-diverse function", GENES TO CELLS, vol. 6, 2001, pages 575 - 597 |
PENNISI, E.: "Search for pore-fection", SCIENCE, vol. 336, 2012, pages 534 - 537 |
See also references of EP2814939A4 |
SONI GV ET AL., REV SCI INSTRUM., vol. 81, no. 1, January 2010 (2010-01-01), pages 014301 |
STODDART D ET AL., PROC NATL ACAD SCI, vol. 106, no. 19, pages 7702 - 7 |
TALAGA, D.S.; LI, J.: "Single-molecule protein unfolding in solid state nanopores", J. AM. CHEM. SOC., vol. 131, 2009, pages 9287 - 9297, XP055242040, DOI: doi:10.1021/ja901088b |
WAWRZYNOW ET AL.: "The ClpX heat-shock protein of Escherichia coli, the ATP-dependent substrate specificity component of the ClpP-ClpX protease, is a novel molecular chaperone", EMBO J., vol. 14, no. 9, 1 May 1995 (1995-05-01), pages 1867 - 1877, XP008023123 |
Cited By (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11768174B2 (en) | 2011-04-04 | 2023-09-26 | President And Fellows Of Harvard College | Method for nanopore sensing with local electrical potential measurement |
US11644437B2 (en) | 2011-04-04 | 2023-05-09 | President And Fellows Of Harvard College | Nanopore sensing by local electrical potential measurement |
US11561216B2 (en) | 2012-02-13 | 2023-01-24 | Oxford Nanopore Technologies Plc | Apparatus for supporting an array of layers of amphiphilic molecules and method of forming an array of layers of amphiphilic molecules |
US11913936B2 (en) | 2012-02-13 | 2024-02-27 | Oxford Nanopore Technologies Plc | Apparatus for supporting an array of layers of amphiphilic molecules and method of forming an array of layers of amphiphilic molecules |
US11959906B2 (en) | 2012-02-16 | 2024-04-16 | Oxford Nanopore Technologies Plc | Analysis of measurements of a polymer |
US10288599B2 (en) | 2012-10-10 | 2019-05-14 | Arizona Board Of Regents On Behalf Of Arizona State University | Systems and devices for molecule sensing and method of manufacturing thereof |
US9274430B2 (en) | 2012-10-10 | 2016-03-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Systems and devices for molecule sensing and method of manufacturing thereof |
US11137386B2 (en) | 2012-10-10 | 2021-10-05 | Arizona Board Of Regents, Acting For And On Behalf Of Arizona State University | Systems and devices for molecule sensing and method of manufacturing thereof |
US10131943B2 (en) | 2012-12-19 | 2018-11-20 | Oxford Nanopore Technologies Ltd. | Analysis of a polynucleotide via a nanopore system |
US11085077B2 (en) | 2012-12-19 | 2021-08-10 | Oxford Nanopore Technologies Ltd. | Analysis of a polynucleotide via a nanopore system |
US9952198B2 (en) | 2013-03-05 | 2018-04-24 | Arizona Board Of Regents On Behalf Of Arizona State University | Translocation of a polymer through a nanopore |
US10267785B2 (en) | 2013-03-05 | 2019-04-23 | Arizona Board Of Regents On Behalf Of Arizona State University | Translocation of a polymer through a nanopore |
US20160209317A1 (en) * | 2013-09-23 | 2016-07-21 | Isis Innovation Limited | Method |
US10712254B2 (en) | 2013-09-23 | 2020-07-14 | Oxford University Innovation Limited | Method of analyzing post-translational modifications |
WO2015040423A1 (en) * | 2013-09-23 | 2015-03-26 | Isis Innovation Limited | Method |
US11592382B2 (en) | 2013-09-23 | 2023-02-28 | Oxford University Innovation Limited | Method of analyzing post-translational modifications |
AU2014322867B2 (en) * | 2013-09-23 | 2020-10-08 | Oxford University Innovation Limited | Method |
CN105765387A (en) * | 2013-09-23 | 2016-07-13 | 伊希斯创新有限公司 | Method |
JP2016532125A (en) * | 2013-09-23 | 2016-10-13 | アイシス イノベーション リミテッド | Method for determining the presence, absence, number or position of one or more post-translational modifications (PTMs) in a peptide, polypeptide or protein |
US10047392B2 (en) | 2014-02-21 | 2018-08-14 | Northeastern University | Fluorescence-based analysis of biopolymers using nanopores |
WO2015127387A1 (en) * | 2014-02-21 | 2015-08-27 | Northeastern University | Fluorescence-based analysis of biopolymers using nanopores |
US10336713B2 (en) | 2014-02-27 | 2019-07-02 | Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University | Triazole-based reader molecules and methods for synthesizing and use thereof |
US10689697B2 (en) | 2014-10-16 | 2020-06-23 | Oxford Nanopore Technologies Ltd. | Analysis of a polymer |
US11401549B2 (en) | 2014-10-16 | 2022-08-02 | Oxford Nanopore Technologies Plc | Analysis of a polymer |
US20160194698A1 (en) * | 2014-12-16 | 2016-07-07 | Arizona Board Of Regents On Behalf Of Arizona State University | Systems, apparatuses and methods for reading polymer sequence |
US11994507B2 (en) | 2015-02-05 | 2024-05-28 | President And Fellows Of Harvard College | Nanopore sensor calibration and operation with a fluidic passage |
JP7229219B2 (en) | 2015-02-05 | 2023-02-27 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Nanopore sensor with fluid passageway |
EP4293349A2 (en) | 2015-02-05 | 2023-12-20 | President and Fellows of Harvard College | Nanopore sensor including fluidic passage |
US10794895B2 (en) | 2015-02-05 | 2020-10-06 | President And Fellows Of Harvard College | Nanopore sensor including fluidic passage |
US11959904B2 (en) | 2015-02-05 | 2024-04-16 | President And Fellows Of Harvard College | Nanopore sensing with a fluidic passage |
WO2016127007A3 (en) * | 2015-02-05 | 2016-10-06 | President And Fellows Of Harvard College | Nanopore sensor including fluidic passage |
US11946925B2 (en) | 2015-02-05 | 2024-04-02 | President And Fellows Of Harvard College | Nanopore sensor having a fluidic passage for local electrical potential measurement |
JP2021060406A (en) * | 2015-02-05 | 2021-04-15 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Nanopore sensor including fluidic passage |
EP3741452A1 (en) | 2015-05-20 | 2020-11-25 | Oxford Nanopore Inc. | Methods and apparatus for forming apertures in a solid state membrane using dielectric breakdown |
US10596523B2 (en) | 2015-05-20 | 2020-03-24 | Oxford Nanopore Inc. | Methods and apparatus for forming apertures in a solid state membrane using dielectric breakdown |
US11986775B2 (en) | 2015-05-20 | 2024-05-21 | Oxford Nanopore Technologies Plc | Methods and apparatus for forming apertures in a solid state membrane using dielectric breakdown |
US11596940B2 (en) | 2016-07-06 | 2023-03-07 | Oxford Nanopore Technologies Plc | Microfluidic device |
US12042790B2 (en) | 2016-11-24 | 2024-07-23 | Oxford Nanopore Technologies Plc | Apparatus and methods for controlling insertion of a membrane channel into a membrane |
WO2020183172A1 (en) | 2019-03-12 | 2020-09-17 | Oxford Nanopore Technologies Inc. | Nanopore sensing device and methods of operation and of forming it |
US11789006B2 (en) | 2019-03-12 | 2023-10-17 | Oxford Nanopore Technologies Plc | Nanopore sensing device, components and method of operation |
NL2023062B1 (en) * | 2019-05-03 | 2020-11-30 | Univ Delft Tech | Protein current trace signal acquisition using a nanopore |
WO2021078971A2 (en) | 2019-10-25 | 2021-04-29 | Oxford Nanopore Technologies Limited | Improved nanopore sensing device, components and method of manufacture |
EP4058549A4 (en) * | 2019-11-15 | 2023-12-27 | Machine Bio Inc. | Methods and systems for generating biological molecules |
EP4270008A3 (en) * | 2019-12-02 | 2024-01-10 | Oxford Nanopore Technologies PLC | Method of characterising a target polypeptide using a nanopore |
WO2021111125A1 (en) | 2019-12-02 | 2021-06-10 | Oxford Nanopore Technologies Limited | Method of characterising a target polypeptide using a nanopore |
EP4270008A2 (en) | 2019-12-02 | 2023-11-01 | Oxford Nanopore Technologies PLC | Method of characterising a target polypeptide using a nanopore |
NL2024579B1 (en) | 2019-12-24 | 2021-09-06 | Univ Delft Tech | Protein and peptide fingerprinting and sequencing by nanopore translocation of peptide-oligonucleotide complexes |
EP4325223A2 (en) | 2019-12-24 | 2024-02-21 | Technische Universiteit Delft | Protein and peptide fingerprinting and sequencing by nanopore translocation of peptide-oligonucleotide complexes |
WO2021133168A1 (en) | 2019-12-24 | 2021-07-01 | Technische Universiteit Delft | Protein and peptide fingerprinting and sequencing by nanopore translocation of peptide-oligonucleotide complexes |
WO2021255414A1 (en) | 2020-06-17 | 2021-12-23 | Oxford Nanopore Technologies Limited | Nanopore support structure and manufacture thereof |
WO2022013551A1 (en) | 2020-07-17 | 2022-01-20 | Oxford Nanopore Technologies Limited | Nanopore sensing device |
WO2022020461A1 (en) | 2020-07-22 | 2022-01-27 | Oxford Nanopore Technologies Inc. | Solid state nanopore formation |
US20220308001A1 (en) * | 2021-03-25 | 2022-09-29 | The Regents Of The University Of California | Apparatus and method for single cell discrimination |
US11994484B2 (en) * | 2021-03-25 | 2024-05-28 | The Regents Of The University Of California | Apparatus and method for single cell discrimination |
WO2023026056A1 (en) | 2021-08-26 | 2023-03-02 | Oxford Nanopore Technologies Plc | Nanopore |
WO2023118891A1 (en) | 2021-12-23 | 2023-06-29 | Oxford Nanopore Technologies Plc | Method of characterising polypeptides using a nanopore |
WO2024091124A1 (en) | 2022-10-28 | 2024-05-02 | Rijksuniversiteit Groningen | Nanopore-based analysis of proteins |
WO2024094986A1 (en) | 2022-10-31 | 2024-05-10 | Oxford Nanopore Technologies Plc | Method |
WO2024100270A1 (en) | 2022-11-11 | 2024-05-16 | Oxford Nanopore Technologies Plc | Novel pore monomers and pores |
WO2024165853A1 (en) | 2023-02-07 | 2024-08-15 | Oxford University Innovation Limited | Method of characterising a peptide, polypeptide or protein using a nanopore |
Also Published As
Publication number | Publication date |
---|---|
BR112014020255A8 (en) | 2017-07-11 |
US11339365B2 (en) | 2022-05-24 |
CA2864824C (en) | 2020-06-16 |
CA2864824A1 (en) | 2013-08-22 |
JP2015517799A (en) | 2015-06-25 |
JP2018075021A (en) | 2018-05-17 |
KR102066758B1 (en) | 2020-02-11 |
EP2814939A2 (en) | 2014-12-24 |
AU2013221356A1 (en) | 2014-08-28 |
KR20140131539A (en) | 2014-11-13 |
AU2013221356B2 (en) | 2018-10-18 |
JP6312607B2 (en) | 2018-04-18 |
EP2814939A4 (en) | 2016-02-24 |
CN104619854A (en) | 2015-05-13 |
JP6594944B2 (en) | 2019-10-23 |
US20220396758A1 (en) | 2022-12-15 |
DK2814939T3 (en) | 2018-07-30 |
EP2814939B1 (en) | 2018-04-18 |
US20160032236A1 (en) | 2016-02-04 |
CN104619854B (en) | 2018-07-17 |
BR112014020255A2 (en) | 2017-06-20 |
BR112014020255B1 (en) | 2022-01-25 |
WO2013123379A3 (en) | 2015-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220396758A1 (en) | Nanopore sensor for enzyme-mediated protein translocation | |
US11845780B2 (en) | Mutant lysenin pores | |
Robertson et al. | The utility of nanopore technology for protein and peptide sensing | |
Nivala et al. | Unfoldase-mediated protein translocation through an α-hemolysin nanopore | |
JP6169976B2 (en) | Mutant pore | |
EP2614156B1 (en) | Control of dna movement in a nanopore at one nucleotide precision by a processive enzyme | |
Wang et al. | Nanopore sensing of botulinum toxin type B by discriminating an enzymatically cleaved peptide from a synaptic protein synaptobrevin 2 derivative | |
Taniguchi | Selective multidetection using nanopores | |
JP2023100625A (en) | Droplet interfaces in electro-wetting devices | |
Motone et al. | Herding cats: Label-based approaches in protein translocation through nanopore sensors for single-molecule protein sequence analysis | |
US20150031024A1 (en) | Enzymatic preparation of 10 base to 50 kb double-strand dna reagent for sequencing with a nanopore-polymerase sequencing device | |
CN107532204A (en) | Double-layer of lipoid integrates SPP1 linker proteins nano-pore and the SPP1 linker protein variants as double-layer of lipoid integrated nanometer hole | |
Zhou et al. | Single-molecule study on interactions between cyclic nonribosomal peptides and protein nanopore | |
US11845779B2 (en) | Mutant aerolysin and uses thereof | |
EP4362028A1 (en) | Mutant aerolysin and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13749423 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2014557827 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2864824 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2013221356 Country of ref document: AU Date of ref document: 20130215 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013749423 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20147025764 Country of ref document: KR Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014020255 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014020255 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140815 |